AU773844B2 - Compositions and methods for regulating lymphocyte activation - Google Patents

Description

J1

AUSTRALIA

PATENTS ACT 1990 DIVISIONAL APPLICATION NAME OF APPLICANT: Xcyte Therapies, Inc.

ADDRESS FOR SERVICE: DAVIES COLLISON CAVE Patent Attorneys 1 Little Collins Street Melbourne, 3000.

INVENTION TITLE: "Compositions and methods for regulating lymphocyte activation" The following statement is a full description of this invention, including the best method of performing it known to us: COMPOSITIONS AND METHODS FOR REGULATING LYMPHOCYTE ACTIVATION 1. INTRODUCTION The present invention relates to regulation of lymphocyte activation. In particular, it relates to compositions and methods for regulating lymphocyte activation by selectively binding multiple cell surface antigens expressed by the same lymphocyte.

Antigen aggregation can be achieved in vitro by incubating lymphocytes with immobilized ligands or antibodies or antibody fragments specific for the target antigens.

In addition, multispecific molecules that contain multiple binding specificities in a single soluble molecule are particularly useful in aggregating multiple antigens in vivo resulting in lymphocyte activation. Multispecific molecules may also be constructed to inhibit Slymphocyte activation by blocking the delivery of activation signals to the cells.

Therefore, the invention is useful in regulating T and B cell immune responses in vitro and in vivo.

2. BACKGROUND OF THE INVENTION 2.1. T CELL RECEPTOR/CD3 COMPLEX Mature T lymphocytes (T cells) recognize antigens by the T cell antigen receptor (TCR) complex. In general, each TCR/CD3 complex consists of six subunits including the clonotypic disulfide-linked TCRa/P or TCRy/6 heterodimers and the invariant CD3 complex M. Davis, Annu. Rev. Biochem., 59:475, A. C. Chan et al., Annu. Rev.

Immunol., 10: 555). The TCR a, P, y, and 6 chains are 40 to 50 kDa glycoproteins encoded by T cell specific genes that contain antibody-like variable joining and constant regions M. Hedrick et al., Nature, 308: 149; S. M. Hedrick et al., Nature, 308: 153). The TCR heterodimers are the antigen binding subunits and they determine the specificity of individual T cells. a/P heteroexpressing cells constitute more than of peripheral T cells in both humans and mice, and they are responsible for the classical helper or cytotoxic T cell responses M. Davis, Annu. Rev. Biochem., 59: 475; A. C. Chan et atl, Annu. Rev. Immunol., 10: 555). In most cases, TCRa/P ligands are peptide antigens presented by the major histocompatibility complex (MHC) Class I or Class II molecules. In contrast, the nature ofTCRy/6 ligands is not as well defined, and may not involve presentation by the MHC proteins Chien et al., Annu. Rev.

Immunol., 15: 511).

The invariant CD3 complex is made up of four relatively small polypeptides, CD36 (20kDa), CD3E (20kDa), CD3y (25 kDa) and CD3C (16kDa). CD38, E, and y chains show a significant degree of similarity to each other in their amino acid sequences. They are members of the immunoglobulin (Ig) supergene family, each of them possesses a single extracellular Ig-like domain. In contrast, CD3C only has a nine amino acid extracellular domain and a longer cytoplasmic domain when compared to CD36, E, and y. The cytoplasmic domains of the CD3 chains contain one to three copies of a conserved motif termed an immunoreceptor tyrosine-based activation motif (ITAM) that can mediate cellular activation. One consequence of TCR/CD3 complex ligation by S"peptide-MHC ligands is the recruitment of a variety of signaling factors to the ITAMs of the CD3 chains. This initiates the activation of multiple signal transduction pathways, eventually resulting in gene expression, cellular proliferation and generation of effector T cell functions Weiss and D. R. Littman, Cell, 76: 263; R. Wange and L. E.

Samelson, Immunity, 5: 197).

The assembly and expression of the TCR complex are complex and tightly *0 regulated processes; exactly how different chains of the receptor complex contribute to these remain to be fully elucidated. Nevertheless, it is well established that surface expression of a TCR complex requires the presence of TCRa/p or TCRy/8 plus CD38 CD3E, CD3y, and CD3C chains Minami et al., Proc. Natl. Acad. Sci. USA., 84: 2688; B. Alaracon et al., J. Biol. Chem., 263: 2953). Absence of any one chain renders the complex trapped in the cytoplasm and subjects them to rapid proteolytic degradation Chen et al., J. Cell Biol. 107: 2149; J. s. Bonifacino et al., J. Cell Biol. 109: 73). The precise stoichiometry of a TCR/CD3 complex is unknown. Several lines of evidence have suggested that one TCR/CD3 complex may contain two copies of the TCR heterodimer, a CD3E/6 heterodimer, a CD3E/y heterodimer and a CD3(C homodimer to constitute a decameric complex S. Blumberg et al., Proc. Natl. Acad. Sci. USA., 87: 7220; M. Exley et al., Mol. Immunol., 32: 829). In this complex, the TCR heterodimers and CD3( homodimers are covalently linked by disulfide bonds, while the CD3E/5 and CD3E/y heterodimers are not covalently linked. Furthermore, the interaction among -2- CD3E/6, CD36/y, CD3C(, and TCRa/P or TCRy/6 chains has been shown to be noncovalent.

Assembly of the TCR/CD3 complex begins with pairwise interactions between individual TCRa, TCRP chains with the CD3 chains in the endoplastmic reticulum (ER) leading to the formation of intermediates consisting of a single TCR chain in association with the CD3 chains Alarcon et al., J. Biol. Chem., 263: 2953; N. Manolios et al., EMBO 10: 1643). Transfection studies conducted in non-lymphoid cells shows that TCRa can associate with CD36 and CD3e but not CD3C whereas TCRp can associate with CD38, E, and y but no CD3C Manolios et al., EMBO 10: 1643; T. Wileman et al., J. Cell Biol., 122: 67). The incorporation of the CD3C chain appears to be the rate- *oo .limiting step for the formation of a mature TCR/CD3 complex. TCRc/P, CD38, E, and y chains are strictly required to be present in the ER before CD3C can assemble with the partial TCR/CD3 complex to form the final product for surface expression Minami et al., Proc. Natl. Acad. Sci. USA., 84: 26880. Association between the TCR and CD3 chains seems to depend largely on the charged amino acid residues in their transmembrane domains. Positively charged amino acid residues are present in the transmembrane domains of the TCRa/P chains, an arginine and a lysine for TCRa and a lysine for TCRp. Negatively charged amino acids are found in the transmembrane domains of the CD3 chains, a glutamic acid for CD3y and an aspartic acid for each of CD3e, 6 and C. Formation of salt bridges due to these charged amino acid is believed to be the main force driving the association between the TCRa/P chains and the CD3 chains Hall et al., Int. Immunol., 3:359; P. Cosson et al., Nature, 351:414). A model for a mature TCR/CD3 complex compatible to the above transfection and biochemistry data has been proposed. In this model, one copy each of CD3E/6, CD3 E/y and CD3(/C form the core of the receptor complex with two copies of TCRa/P on the outside. TCRa and TCRP chains may pair with CD36, e or y. The disulfide-linked CD3(C may preferentially pair with TCRa due to the additional negatively charged amino acid in the transmembrane domain of TCRa.

Although the assembly and expression of the TCR/CD3 complex have been extensively studies, relatively little is known about the potential functions of the extracellular domains of the CD36, E or y chains. Recent studies on the crystal structure -3of a TCR-anti-TCR complex has provided evidence for the presence of a binding pocket in the TCRP chain large enough to accommodate the extracellular domain ofCD3E H. Wang et al., EMBO 17:10; Y. Ghendler et al., J. Exp. Med., 187:1529). On the other hand, using deletional analysis a region proximal to the transmembrane domains of the CD38, E or y chains with a conserved Cys-X-X-Cys motif has been implicated to mediate CD3 chain hetero-dimerization Borroto et al., J. Biol. Chem., 273: 12807).

Members of the Ig supergene family are well known for their functions as adhesion molecules. Therefore it is not surprising that ligands may exist for the extracellular domains of CD3 of Ig-like domains. Accordingly, the interaction between CD3 chains and their potential ligands may play crucial roles in regulating T lymphocyte activation.

The absence of a system to produce soluble CD3 complexes in their native conformations is one underscoring reason for a lag of information on functions of the extracellular domains of the CD3 chains. Numerous monoclonal antibodies (mAbs) have been raised against the TCR/CD3 complex; many of them specifically recognize the CD3 complex. Moreover, the reactivity of most anti-CD3 mAbs falls into two categories: anti-CD3 mAbs that can recognize the CD3E chain alone and anti-CD3 mAbs that only recognize a conformation epitope believed to be generated by a native interaction between the CD3E chain and either the CD38 or CD3y chain Salmeron et al., J. Immunol., 147:3047). The latter have been applied to visualize formation of native CD3E/6 and CD3E/y heterodimers in the cytoplasm of non-lymphoid cells transfected with the corresponding cDNA clones chain Salmeron et al., J. Immunol., 147:3047).

2.2. LYMPHOCYTE ACTIVATION BY TRIGGERING SURFACE

RECEPTORS

Production of mAbs against lymphocytes has led to the identification of a large number of lymphocyte surface antigens. Expression of these antigens by subsets of lymphocytes has been used to classify T and B cells into specific functional subpopulations and different differentiation stages. More recently, certain of these surface antigens have been recognized as capable of mediating activation signals. Most notably, antibodies directed to CD3 have been used to activate T cells in the absence of antigen (Leo et al, 1987, Proc. Natl. Acad. Sci. U.S.A. 84:1374). In addition, studies of T cell activation have shown that ligand binding to specific coreceptors modifies T cell proliferation and cytokine production initiated by stimulation of the TCR/CD3 complex.

It has been observed that clustering of certain surface antigens as coreceptors results in enhanced T cell activation. Several approaches for using ligands to mediate receptor clustering have been developed. For example, ligands have been immobilized on beads or on plastic surfaces, causing the bound receptors to cluster at the site of contact between the cell and the artificial surface. Receptors have also been clustered together using soluble ligands in the form of bispecific molecules or using a second-step reagent that reacts with two or more monospecific ligands after they have bound to their respective receptors to mediate clustering. Signal transduction experiments and in vitro cell activation experiments using these approaches have generated evidence for functional receptor-coreceptor interactions. However, no acceptable composition for in vivo therapy has been generated.

Aggregation of CD2 with CD3 or CD4 with CD3 has been shown to activate T cells more potently than aggregation of CD3 alone (Ledbetter et al., 1988, Eur. J.

Immunol. 18:525-532; Wee et al., 1993, J. Exp. Med. 177:219). Similarly, aggregation of other receptors, including CD18 or CD8 with CD3 enhances signal transduction and activation when compared to aggregation of CD3 alone.

While multiple costimulatory receptors have been identified, knowledge of their relationships to each other, and the spatial and temporal requirements for costimulatory effects on CD3 activation are limited. In one study, co-immobilization of ligands for CD18, CD28, and TCR were studied (Damle et al., 1992, J. Immunol. 149:2541).

Indirect immobilization of ICAMI-Ig, B7-Ig and anti-TCR using anti-Ig coated on plastic plates augmented anti-TCR dependent proliferation more than immobilization of ICAMI-Ig or B7-Ig individually. However, ICAMI-Ig was more effective for resting T cells, whereas B7-Ig was more effective for previously activated T cells, implying that the interaction between these coreceptors may be temporal rather than physical.

Although multiple coreceptors modify activation responses through the TCR complex, there is limited information about how these coreceptors work together in aggregate. Clustering of three or more receptors such that each makes a functional contribution to activation signals and overall cellular response has not been well studied.

Studies of B cell activation have also revealed the presence of multiple coreceptors that modify the activation signals and responses initiated by binding to the B cell antigen receptor complex. Notable examples of these receptors include CD19, CD21, CD22, CD40 and surface immunoglobulin Receptor-coreceptor interactions have been demonstrated by using soluble ligands crosslinked together on the cell surface with second step reagents, soluble bispecific molecules such as heteroconjugated antibodies, or combinations of ligands immobilized on a solid surface.

Although multiple coreceptors are known, the functional interactions of three or more receptors on B cells have not been reported.

3. SUMMARY OF THE INVENTION The present invention relates to compositions and methods for regulating lymphocyte activation. In particular, the invention relates to compositions and methods for activating T and/or B cells by aggregating three or more cell surface antigens. The activation signals may result in either immune enhancement or immunosuppression.

The invention also relates to inhibition of lymphocyte activation by simultaneous binding to multiple surface receptors and blocking or inhibiting their ability to transmit activation signals and/or by preventing their ability to bind and activate receptors on other cells.

In one embodiment the invention expands the number of T and/or B cells in vitro

C.

and in vivo by aggregating three or more surface antigens. Expanded T and B cells are used in adoptive immunotherapy of cancer and infectious diseases such as acquired immunodeficiency syndrome (AIDS). A preferred method for aggregating multiple cell surface antigens in vitro is by adsorption of ligands that bind cell surface antigens and/or antibodies specific for the antigens or their antigen-binding derivatives such as variable domains and complementarity-determining regions (CDRs) of variable domains, onto a solid substrate such as a culture dish or suspendable beads.

While ligands, antibodies or their antigen-binding derivatives may be adsorbed on a biodegradable substrate for in vivo administration, it is preferred that these molecules be combined to form a single soluble multivalent molecule by chemical conjugation or recombinant expression methods. Therefore, in another embodiment the -6invention provides a multispecific molecule that simultaneously binds to multiple cell surface antigens. Such multispecific molecule may be immobilized for in vitro lymphocyte activation, or it may be administered as a pharmaceutical composition to a subject for the regulation of lymphocyte activation in vivo. A multispecific molecule may activate lymphocytes by aggregating multiple surface receptors or inhibit lymphocyte activation by interfering with ligand/receptor interactions between T and B cells or between lymphocytes and antigen-presenting cells. A wide variety of uses are encompassed by this aspect of the invention, including but not limited to, treatment of immunodeficiency, infectious diseases and cancer as well as suppression of autoimmunity, hypersensitivity, vascular diseases and transplantation rejection.

The present invention is based, in part, on Applicants' discovery that stimulation of human T cells with immobilized antibodies specific for three T cell surface antigens resulted in enhanced proliferation when compared with stimulation by two immobilized antibodies. Therefore, aggregation of three T cell surface antigens enhanced T cell proliferation. The invention is also based, in part, on Applicants' discovery that llamas immunized with human T cell surface antigens produced antibodies devoid of light chains that bound to such antigens. Since these heavy chain-only antibodies can be generated in llamas against human cell surface antigens, these antibodies and their antigen-binding derivatives are preferred in the construction of multispecific molecules because the lack of light chain participation in antigen binding eliminates the need to S"include light chains or light chain variable regions. Thus, the use of heavy chain-only antibodies in the construction of multispecific molecules makes the formation of their binding sites less complex. Furthermore, such antibodies contain longer CDRs, especially CDR3, than antibodies composed of heavy and light chains, indicating that CDR peptides derived from heavy chain-only antibodies may be of higher affinity and stability for use in the construction of multispecific molecules.

In another embodiment the invention provides multispecific molecules using heavy chain-only antibodies obtained from the Camelidae family, their variable domains known as VH or the antigen-binding CDRs derived therefrom. Such multispecific molecules are useful for immunoregulation, based on either stimulation or inhibition of lymphocyte activation. In an effort to enrich for B cells producing this class of -7containing antibodies, Applicants also discovered that llama B cells express a human epitope cross-reactive with an anti-human CD40 antibody, and a subpopulation of llama cells express heavy chain-only antibodies. Furthermore, the CD40' cells could be activated to proliferate by an anti-CD40 antibody. Hence, it is an object of the invention to enrich for llama B cells that express heavy chain-only antibodies on the basis of their co-expression of CD40 and immunoglobulins without light chains, and to expand their numbers by CD40 stimulation. The expanded cells are particularly useful as a source of mRNA for the construction of libraries of V, domains and selection of antigen-binding specificities. A novel subclass of such VHH from L. llama are shown in the working examples as lacking a CH1 domain, and their CDR1, CDR2 and CDR3 are not linked by disulfide linkages.

In yet another embodiment the invention provides a method to convert a conventional antibody such as a murine antibody to a heavy chain-only antibody in a process referred to as llamalization. The llamalized antibody retains its original antibody i binding specificity without pairing with a light chain.

In another embodiment the invention provides a method to construct fusion proteins between an antibody variable region or a human antigen and llama constant regions. Such fusion proteins are particularly useful in llama immunization to generate VHH against the non-llama epitopes.

In yet another embodiment the invention generates soluble human CD3 heterodimers.

4. BRIEF DESCRIPTION OF THE DRAWINGS Figure 1. A schematic description of the isolation of llama VHH polypeptides that bind to cell surface antigens.

Figure 2. Immobilized mAbs specific for three T cell surface antigens induced enhanced proliferation of human blood T cells.

-8- Figure 3.

Figure 4.

Figure 5A 5B.

Figure 6.

Figure 7A 7B.

Figure 8.

Figure 9A-9F.

Figure 10A- OF.

0 0 *0 *5 5S *5 Immobilized anti-CD3, anti-CD28 and mAbs induced enhanced proliferation of T cells.

Synergy between CD2, CD3 and CD28 activation of purified CD4 T cells as compared to activation of CD8* T cells.

Stimulation of T cells with immobilized anti-CD2, anti-CD3 and anti-CD28 antibodies resulted in cell growth (5B) in direct correlation with 3 H-thymidine incorporation measurements Synergistic effects of mAbs against CD3, CD2 and CD28 co-immobilized on "DYNAL" beads.

Comparison of co-immobilized and separately immobilized mAbs on T cell proliferation. CD3 x CD28 anti-CD3 and anti-CD28 mAbs coimmobilized on same beads. CD3 x CD2 anti-CD3 and anti-CD2 mAbs co-immobilized on same beads.

CD3 CD28 a mixture of beads coated with anti- CD3 or anti-CD28 mAb. CD3 CD2 a mixture of beads coated with anti-CD3 or anti-CD2 mAb.

Anti-CD2 in solution or coated on separate beads inhibited co-immobilized anti-CD3 and anti-CD28 in T cell activation.

Selective growth ofT cells expressing VP TCR chains.

Llama B cells express CD40 and surface immunoglobulin and certain CD40* cells express Ig that do not contain light chain. Llama peripheral blood lymphocytes were unstained or stained with antibodies: anti-CD40 and anti-light chain (10C), antilight chain (10D), anti-CD40 and anti-Ig (10E) and anti-Ig (1OF).

-9- Figure 11.

*.0 0 1 Figure 12.

Figure 13A-13H.

Figure 14.

Figure 15.

Figure 16A-16B.

Figure 17.

Llama B cells proliferated in response to stimulation with an anti-CD40 antibody and CD86 (or B7.2)expressing transfected CHO cells plus PMA. Results from two different llamas are shown.

SDS-PAGE analysis of fractionated Llama antibodies.

Lane 1 contains IgGI D (DEAE flowthrough), lane 2 contains IgG I G (Protein G-bound antibodies eluted at pH lane 3 contains IgG2 and IgG3 (Protein Gbound antibodies eluted at pH 3.5) and lane 4 contains IgG3 (Protein G flow through). Lanes 3 and 4 show antibody heavy chain without light chain.

Llama heavy chain-only antibodies (IgG2 and IgG3) bound human T cell surface antigens. Jurkat T cells were stained with IgGI G (13A), IgGI D (13C), IgG2 IgG3 (13E) or IgG3 (13G) followed by a second step anti-Ig reagent. Jurkat T cells were also stained with the same antibody fractions (13B, 13D, 13F and 13H), followed by a second step anti-light chain reagent.

Camelid VnH phage display vector.

Phage clones, L10 and L11, reacted with a high molecular weight protein expressed on CHO cell surface.

Amino acid sequence alignment of Llama VH polypeptides. 16A shows alignment of several unique hybrid sequences (SEQ ID NOS: 16B shows alignment of several complete sequences (SEQ ID NOS: 10-15) which are similar to previously reported camel variable regions.

Llama constant region sequences (SEQ ID NOS: 16- 21).

Figure 18. Oligonucleotides for antibody 9.3 llamalization (SEQ ID NOS: 22-46). Overlapping oligonucleotides were used to resynthesize 9.3 V, wide type and llamalized version 1(LV 1) and version 2 (LV2). The blank spaces for llamalized oligonucleotides are identical to the widetype, thus only altered residues are listed.

Figure 19. FACS analysis ofJurkat T cells stained by Ilamalized 9.3 V

H

Figure 20. Binding activity of various CD3-Ig fusion proteins to g* anti-CD3 mAbs, G19-4.

g 5. DETAILED DESCRIPTION OF THE INVENTION Multiple antigens (or receptors) expressed by lymphocytes work together to regulate cellular activation. In many cases, receptors work together by coming into close proximity or make contact with e.ch other to collectively mediate an activation signal.

"Under physiological conditions, this process may be controlled by cell-cell contact, where ligands expressed by one cell contact receptors expressed by a second cell, and the receptors are crosslinked and clustered at the site of cell-cell contact. The precise array and order of the receptor contacts may be controlled by the spatial orientation of the ligands and by the inherent ability of the receptors to contact each other at specific sites and in a specific order. The activation signals that are mediated by clustered receptors depend upon intrinsic enzymatic activity of the receptors or of molecules that are directly or indirectly (through linker molecules) associated with each receptor. The clustered receptors allow signaling complexes to form at the cell membrane that result in composite signals dependent upon the precise makeup and orientation of the clustered receptors. Changes in the pattern of receptor clustering result in altered activation states of the resident cell.

The following sections describe compositions and methods for mimicking receptor clustering by aggregating lymphocyte antigens to generate an activation signal.

Although the specific procedures and methods described herein are exemplified using immobilized antibodies specific for three T cell antigens, they are merely illustrative for 11 the practice of the invention. Analogous procedures and techniques, as well as functionally equivalent compositions, as will be apparent to those skilled in the art based on the detailed disclosure provided herein are also encompassed by the invention.

5.1. LYMPHOCYTE SURFACE ANTIGENS Studies of T and B cell activation have identified a number of cell surface antigens which directly or indirectly mediate activation signals. An "activation signal" as used herein refers to a molecular event which is manifested in a measurable cellular activity such as proliferation, differentiation, cytotoxicity and apoptosis, as well as secretion of cytokines, changes in cytokine profiles, alteration of expression levels or distribution of cell surface receptors, antibodies production and antibody class switching.

In addition, an "activation signal" can be assayed by detecting intracellular calcium mobilization and tyrosine phosphorylation of receptors (Ledbetter et al., 1991, Blood 77:1271).

In addition to the TCR/CD3, other molecules expressed by T cells which mediate an activation signal, include but are not limited to, CD2, CD4, CD5, CD6, CD8, CD18, CD27, CD28, CD40, CD43, CD45, CD45RA, CD45RO, CDwl50, CD152 (CTLA-4), CD154, MHC class I, MHC class II, CDwl37 (4-1BB), (The Leucocyte Aiitigen Facts Book, 1993, Barclay et al., Academic Press; Leucocyte Typing, 1984, Bernard et al. Springer-Verlag; Leukocyte Typing II, 1986, Reinherz et al. (eds.), Springer-Verlag; Leukocyte Typing III, 1987, McMichael Oxford University Press; Leukocyte Typing IV, 1989, Knapp et al. Oxford University Press; CD Antigens, 1996, VI Intemat. Workshop and Conference on Human Leukocyte Differentiation Antigens. http://www.ncbi.nlm.nih.gov/prow), ICOS (Hutloffet al., 1999, Nature 397:263-266), a cytokine receptor and the like. Cell surface antigens that work together with TCR/CD3 are often referred to as co-receptors in the art.

Specific antibodies have been generated against all of the aforementioned T cell surface antigens, and they are commercially available. Other molecules that bind to the aforementioned T surface antigens include antigen-binding antibody derivatives such as variable domains, peptides, superantigens, and their natural ligands or ligand fusion proteins such as CD58 (LFA-3) for CD2, HIV gpl20 for CD4, CD27L for CD27, -12 or CD86 for CD28 or CD152, ICAM1, ICAM2 and ICAM3 for CD1 la/CD18, 4-1BBL for CDw137. Such molecules collectively referred to herein as "binding partners" of surface antigens may be used to deliver or inhibit an activation signal to T cells. For the activation of certain antigens, multiple ligands may be used to achieve the same outcome. For example, B7.1 (CD80), B7.2 (CD86) and B7.3 may be used to activate CD28. B7.3 is a recently identified member of the CD80/CD86 family (GenBank Database Accession No. Y07827). Alignment of the amino acid sequence of B7.3 with those of other family members shows that it is as similar to B7.1 and B7.2 as B7.1 is similar to B7.2.

Activation molecules expressed by B cells, include but are not limited to, surface gIg, CD18, CD19, CD20, CD21, CD22, CD23, CD40, CD45, CD80, CD86 and ICAM1.

Similarly, natural ligands of these molecules, antibodies directed to them as well as antibody derivatives may be used to deliver or inhibit an activation signal to B cells.

In a specific embodiment illustrated by examples in Section 6, infra, the present invention demonstrates that aggregation of CD2 and CD3 plus CD28 or CD4 or enhanced T cell proliferation. In accordance with this aspect of the invention, any three or more up to ten of the aforementioned T and B cell antigens may be bound and aggregated to induce T and B cell activation. For T cell activation, the preferred antigen combinations include CD2 and CD3 with a third antigen being variable, including CD4, CD5, CD6, CD8, CD18, CD27, CD28, CD45RA, CD45RO, CD45, CDwl37, CD152 or CD154. In addition, it is also preferred that CD2 and CD3 are aggregated with two or three of these surface antigens in any combinations. Examples of these combinations include CD2 and CD3 plus CD4 and CD5 or CD4 and CD28 or CD5 and CD28 or CD8 and CD28 or CDwl37 and CD28 or CD4 and CDS and CD28. For B cell activation, the preferred combinations include CD80 and CD86 with a third antigen being variable, including CD40 or CD56. In addition, CD40 may be aggregated with and CD86 or with CD19 and CD20. In another preferred embodiment, the antigen combination includes CD3 or TCR and CD28 plus a third antigen described above.

13- 5.2. METHODS FOR AGGREGATING

MULTIPLE

LYMPHOCYTE SURFACE ANTIGENS One aspect of the present invention relates to methods of aggregating a specific set of three or more antigen combinations to induce lymphocyte activation. A convenient method for aggregating multiple cell surface antigens is by immobilizing "binding partners" of the antigens on a solid substrate such as adsorption on a culture dish, on beads, or on a biodegradable matrix by covalent or non-covalent linkages. In a preferred embodiment, the binding partners are coated on beads, which can be readily separated from cells by size filtration or a magnetic field. While such "binding partners" include natural ligands, binding domains ofligands, and ligand fusion proteins, the preferred embodiments for the practice of this aspect of the invention are antibodies and their antigen-binding derivatives such as Fab, (Fab') 2 F, single chain antibodies, heavy chain-only antibodies, VHH and CDRs (Harlow and Lane, 1988, Antibodies, Cold Spring Harbor Press; WO 94/04678). These molecules may be produced by recombinant methods, by chemical synthetic methods or by purification from natural sources. An alternative method to immobilization is cross-linking of three or more antibodies or their antigen-binding derivatives with a secondary antibody that binds a commonly shared epitope. In cases where the molecules are biotinylated, avidin or streptavidin may be used as a second step cross-linking reagent.

In order to adsorb the appropriate antibodies or their antigen-binding derivatives on a solid substrate, the molecules are suspended in a saline such as PBS at a concentration of 1-100 pg/ml. It is preferred that the concentrations are adjusted to pg/ml. After incubation upon a solid surface at 4-37 0 C for 1-24 hours, extensive washing is performed to remove the free molecules prior to the addition of cells.

Alternatively, antibodies may be covalently conjugated to beads.

Recently, Delamarche et al. (1997, Science 276:779) described the use of microfluidic networks to pattern proteins on a variety of substrates. Such networks may be used to confine an antibody to a specific area of the substrate, so that the cells added thereon are exposed to a different antibody in an orderly fashion as they move through the substrate. As a result, cell surface antigens are aggregated by the antibodies in a sequential order to achieve optimal activation. For example, T cells may be exposed to -14antibodies to achieve aggregation of surface antigens in the order of CD2-CD3-CD4.

Since CD2 and CD4 are located next to CD3, this order of aggregation results in optimal T cell activation. In contrast, aggregation orders of CD2-CD4-CD3 or CD4-CD2-CD3 are expected to be less optimal because in these orders, aggregation of CD2 with CD4 can prevent them from interacting with CD3. The ratios, order and spatial orientation of the binding partners may be adjusted in accordance with a desired outcome.

This aspect of the invention is particularly useful for expansion of lymphocytes in cultures. For the preparation of lymphocytes, peripheral blood mononuclear cells are *i isolated according to standard procedures and added to the culture dishes containing immobilized antibodies. In addition, T or B cell preparations may be enriched prior to stimulation, using methods well known in the art, including but not limited to, affinity methods such as cell sorting and panning, complement cytotoxicity and plastic adherence. Similarly, distinct T and B cell subsets may be purified using these procedures. Generally, the cells are stimulated for a period of several days to a week followed by a brief resting period and restimulation. Alternatively, the expanded cells may be restimulated every three to fourteen days. In order to facilitate the expansion of cell numbers, growth factors such as IL-2 and IL-4 may be added to the cultures. When the mAbs are attached to a solid surface or beads, stimulatory cytokines may also be similarly attached to the same solid support.

In order to aggregate multiple lymphocyte antigens in vivo, the antibodies and their antigen-binding derivatives may be adsorbed onto a biodegradable substrate made of natural material such as cat gut suture or synthetic material such as polyglycolic acid, However, it is preferred that a single soluble molecule with multiple antigen-binding specificities be used for in vivo administration. In fact, such soluble multispecific molecules are also preferred for in vitro lymphocyte activation when they are immobilized. The following section describes the construction of such molecules.

5.3. MULTISPECIFIC MOLECULES THAT AGGREGATE MULTIPLE LYMPHOCYTE SURFACE ANTIGENS Soluble molecules that bind to multiple cellular target antigens have advantages over molecules immobilized on a particulate matrix for in vivo regulation of the immune system. These advantages include the ability of soluble molecules to rapidly diffuse throughout the immune system, and the formulation of a pharmaceutical composition without an immobilization matrix. Soluble multispecific molecules have advantages over combinations of monospecific molecules in specificity and avidity, resulting in increased potency and effectiveness. A multispecific molecule also possesses an increased target cell specificity even though individual components lack specificity for a particular cell type. Several low affinity (<50 nm) binding sites specific for distinct target antigens may be fused in tandem to form a multispecific protein with increased binding avidity for the cells expressing all target antigens. For example, even though CD 18 is expressed by all lymphocytes, a multispecific molecule composed of a CD18binding partner may still exhibit lymphocyte subset specificity because a lymphocyte subset expressing CD 18 and not the other target antigens of the multispecific molecule would not bind the molecule with high avidity.

Regulation of the immune system includes lymphocyte activation, incomplete stimulation signals that do not result in full activation, causing apoptosis or anergy of, lymphocytes, and blockade of multiple receptor-ligand interactions simultaneously. In addition, activation of cells to secrete inhibitory cytokines could result in active suppression of specific responses. In that regard, T cells may be activated to become "TH,"-like cells and induced to secrete TGFP and IL-10 which suppress immune responses by IL-4 production plus a signal to TCR/CD3. Cytokines such as IL-4 may be covalently attached to a solid support or otherwise immobilized with antibodies or ligands to induce TH, T cell differentiation. A multispecific molecule may be constructed between a low affinity (<100 nm) CD3 binding site and binding sites for CD2 and CD4 for that purpose. For T cell activation, a preferred multispecific molecule is composed of binding partners that aggregate CD2, CD3 and CD28. Other T cell activation multispecific molecules are composed of binding partners that aggregate CD2 -16and CD3 or CD3 and CD28 with a third variable antigen such as those described in Section supra.

Also within the scope of the present invention are soluble multispecific molecules that inhibit T and B cell activation. Such inhibitory molecules can bind two, three and up to ten antigens on the same surface simultaneously and inhibit the delivery of an activation signal through these antigens. An example of one such multispecific molecule binds to CD80, CD86, and CD40 on antigen presenting cells and B cells, and interferes with activation of the CD28 pathway and the CD40 pathway simultaneously.

A bispecific inhibitor of the CD28 and CD40 pathways binds to CD28 and CD 154 (the CD40 ligand) on T cells, blocking activation of CD28 and preventing CD154 from activating CD40. Other T cell inhibitory bispecific molecules target CD20 and CD40 or CD2 and CD4 or CD28 and CD45 or CD2 and CD154. Trispecific inhibitory molecules target CD2 and CD28 and CD45 or CD2 and CD4 and CD45 or CD2 and CD4 and CD28 or CD2 and CD27 and CD28.

So'uble multispecific molecules that bind to multiple B cell receptors and enhance activation signals are particularly advantageous for induction ofapoptosis of malignant B cells. Such multispecific molecules also have advantages in specific targeting since they are expected to bind more strongly to a cell that expresses all of the receptors and bind less well to any cell that expresses only one or a subset of the receptors recognized by the multispecific molecules. A preferred multispecific molecule binds to CD19, CD20, and CD40 receptors simultaneously, and generates activating signals through these receptors to result in apoptosis of malignant B cells. Bispecific and multispecific B cell inhibitory molecules may target CD80 and CD40 or CD86 and or CD80 and CD86 or CD80 and CD86 and B7-3 on B cells or antigen presenting cells.

A multispecific molecule may be produced by chemical conjugation of multiple binding partners that bind cell surface antigens or by recombinant expression of polynucleotides that encode these polypeptides. In an effort to reduce the complexity of ligating multiple polypeptide chains such as those seen in antibodies or their coding sequences, it is preferred that single chain polypeptides of low molecule weight be used as binding partners to construct multispecific molecules. In that connection, it has been 17reported in W094/04678 that camels secrete antibodies devoid of light chains. The variable domain of such heavy chain-only antibodies referred to as V, are fused directly to a hinge region which is linked to the CH2 and CH3 domains. The absence of a CH1 domain in the heavy chains prevents formation of disulfide linkages with light chains.

Heavy chain-only antibodies are particularly suitable for use in the construction ofmultispecific molecules because there is no participation in antigen binding by light chains. VH domains of these antibodies are even more suitable because the removal of their constant domains reduces non-specific binding to Fc receptors. Section 8, infra, demonstrates that VHH domains of L. llama contain CDR3 that are longer than CDRs in conventional antibodies, and the CDRs of a particular subclass (hybrid subclass) of these VHH sequences do not form disulfide linkages with other CDRs in the same variable domain. Therefore, these CDRs may be more stable and independent in antigen binding, and can be readily expressed to result in proper folding. The unique features of this class of CDRs render them particularly suitable for use in the construction of multispecific *molecules. The CDRs in these antibodies can be determined by methods ;vl1 known in the art Patent No. 5,637,677), and used for the production of multispecific molecules.

Variable region sequences from L. llama are similar to sequences in the human

VH

3 family of variable domains (Schroeder et al., 1989, Int. Immunol. 2:41-50). In order to reduce immunogenicity of VHH molecules for use in a human recipient, amino acids in non-CDR or exposed framework sites may be altered on the basis of their differences from human VH, residues. Crystal structure of a camel V, can be used as a guide to prioritize residue changes based on the extent of exposure (Desmyter et al., 1996, Nat. Struct. Biol. 3:803-811). Other methods of predicting immunogenicity of residues may also be used hydrophilicity or MHC binding motifs) to guide the choice of residue substitutions. Residues within or adjacent to CDRs that are critical for antigen binding should be preserved in order to avoid a reduction in binding avidity.

Similarly, framework residues that are identified as important in eliminating the hydrophobic VL-VH interface should be preserved for optimal folding and expression of VHH molecules.

-18- In a specific embodiment illustrated by examples in Section 7, infra, heavy chainonly antibodies purified from a llama immunized with human T cells bound to T cell surface antigens. Figure 1 provides a scheme for rapidly screening and selecting VHH domains with cell surface antigen-binding specificities. For the generation of VHH domains, animals belonging to the Camelidae family are used as hosts for immunization with a purified antigen, fusion protein between a human cell surface antigen and llama antibody constant region, or cells expressing an antigen of interest. These hosts, include but are not limited to, old world camelids such as Camelus bactrianus and C.

dromaderius, and new world camelids such as Llama paccos, L. glama, L. vicugna and L. llama. After immunization, peripheral blood leukocytes or mononuclear cells from other lymphoid tissues such as lymph nodes and spleens are isolated by density gradient ":""centrifugation and their cDNA obtained by reverse transcription/polymerase chain reaction as described in Section infra. Phage display technology may be used to express the isolated VHH fragments for the selection of antigen-specific binding VHH Patent Nos. 5,223,409; 5,403,484 and 5,571,698). Examples of a number of isolated VjH sequences from L. llama are shown in Section 8 infra.

Heavy chain-only antibodies may also be produced by conventional hybridoma technology originally described by Koehler and Milstein, 1975, Nature 256:495-497.

Monoclonal heavy chain-only antibodies may be proteolytically cleaved to produce V domains.

Isolated VHH domains or multispecific molecules composed of V, domains may be fused with a second molecule with biologic effector functions. For example, they may be fused with a toxin such as pseudomonas exotoxin 40 (PE40) for specific delivery to kill unwanted cells such as cancer cells or autoreactive T cells. They may also be fused with cytokines to deliver signals to specific cell types, or with extracellular domains of receptors or receptor binding domains to combine receptor specificity with the specificity of VHH. In addition, they may be fused with Ig Fc domains, Ig Fc domains containing specific mutations Patent No. 5,624,821), or portions of Fc domains to construct chimeric antibody derivatives. They may be fused with intracellular targeting signals to allow specific binding to antigens located inside cells. They may be fused with proteins that act as enzymes or that catalyze enzyme reactions. In addition, the 19multispecific molecules may be expressed as genes to improve and/or simplify gene therapy vectors.

5.3.1. CONSTRUCTION OF MULTISPECIFIC

MOLECULES

A preferred method of making soluble multispecific molecules is the fusion of multiple camelid VH variable regions, each specific for a chosen cellular target antigen.

Llamas are a preferred camelid species as a source of such variable regions because they are readily available. The functional activity of a multispecific molecule depends upon the composition, spacing, and ordering of the binding sites of the variable regions.

Composition of the binding sites would depend upon the specificity of the individual VHH used and the number of each VHH in the molecule. VH target specificity may include one or more VHH binding domains against a single receptor fused to other VHH domains targeted to a second or a third receptor. Molecules that target two or more epitopes on only one receptor are within the scope of the invention. These molecules have increased binding avidity for the target and crosslink a single receptor on the cell surface by binding to multiple epitopes. The order of V, domains and receptor epitopes Smay be important for driving intra- or inter-receptor binding patterns. The spacing of the binding sites would depend upon the choices of linkers used between VHH domains.

""Linker length and flexibility are both factors that would control spacing between binding domains. Ordering of the binding sites would be controlled by ordering the VHH domains within the fusion protein construct.

Camelid VH, domains with binding specificity for lymphocyte antigens or CDRs derived from them could be linked together in tandem arrays, either genetically or chemically. If the arrays are genetically linked, fusion proteins are created with multiple antigen binding specificities in a single molecule. In the preferred multispecific structure, the linked molecules should result in the same spectrum of activity, so that blocking, inhibitory molecules are linked to create a more potent immunosuppressive agent. Similarly, agonists that aggregate and stimulate the bound receptors would be linked in order to achieve more potent activation of the lymphocytes bound through their receptors for potential ex vivo cell therapy applications with soluble or immobilized molecules.

The linkers used in either the suppressive or activator molecules might take one of several forms, with the preferred linkers containing repeated arrays of the amino acids glycine and serine. As an example, (gly 4 ser) 3 or (gly 3 ser 2 3 are two preferred choices of linker between antigen binding domains. This linker might need to be lengthened in order to achieve optimal binding of the flanking VHH domains, depending on the size and spacing of the target antigens on the cell surface.

The configuration ofVHH domains might be altered in successive embodiments to determine which structures give the optimal biological effect. In a trispecific molecule, the VH, domain in the center of the molecule might be most constrained and therefore might have an apparent decrease in avidity for its target relative to the two flanking domains. Similarly, some VHH domains might be more sensitive to amino versus carboxy terminal fusions. The suppressive effects of a CD80-CD86-CD40 structure might therefore differ from a CD80-CD40-CD86, CD40-CD80-CD86, CD40-CD86or a CD86-CD40-CD80 type molecule.

53.2. PRODUCTION OF MULTISPECIFIC MOLECULES BY CHEMICAL CONJUGATION METHODS A multispecific molecule may be constructed by chemical conjugation of three or more individual molecules. Glennie Trutt (1990, Bispecific Antibodies and Targeted Cellular Cytotoxicity, pp. 185, Romet-Lemonne describe a method for constructing trispecific antibodies using chemical methods. Briefly, trispecific F(ab') 3 can be constructed by first preparing a bispecific derivative containing the two Fab' arms, and linking it to a third Fab' arm. from two antibodies are first reduced to yield Fab'(SH) and all the available sulfhydryl groups on one antibody Fab'(SH) are maleimidated with a bifunctional cross-linker o-phenylenedimaleimide (o-PDM) followed by reacting Fab' (mal) with the Fab' (SH) under conditions which favor a reaction between SH and maleimide groups while minimizing the reoxidation of SHgroups. After isolating the bispecific F(ab), by column chromatography, it is reduced -21 and linked to Fab'(mal) from a third antibody. All derivatives are reduced and alkylated to safeguard against any minor untoward products which may form by disulfide exchange or oxidation of SH-groups during an overnight incubation. All multispecific Fab' derivatives are passed through a highly specific anti-mouse Fcy immunosorbent to remove any trace amounts of parent monoclonal IgG which may have escaped with the parent F(ab') 2 fragments following fractionation of the digest mixture.

The aforementioned protocol was originally designed for linking Fab fragments from mouse IgG to form trispecific (Fab') 3 through tandem thioether linkages of the hinge-region sulfhydryl groups using the cross-linker o-PDM. However, this method may be adjusted for linking any three or more molecules for the construction of S. multispecific molecules, including, but not limited to, ligands, binding domains of i ligands, antibodies, Fv, VHH and CDR.

5.3.3. PRODUCTION OF MULTISPECIFIC MOLECULES BY RECOMBINANT METHODS The multispecific molecules containing VH, domains will show improvements in expression levels in many cell systems, including bacterial expression, yeast expression, 0. insect expression and mammalian expression systems. The characteristic changes in V, domains allow expression without requiring pairing with a light chain variable region through a strong hydrophobic interaction. Conventional variable regions are not secreted or expressed on the cell surface without pairing with a second variable region to mask the hydrophobic variable region interface. Therefore the expression of variable regions is linked to the hydrophobic interface that mandates pairing with a second variable region. VH domains are expressed individually and should be expressed at much higher levels because of the alterations in hydrophobic residues that restrict expression.

The multispecific molecules containing V, domains also will express better because they can be folded into their active conformations more easily. This will be a significant advantage in bacterial expression where active molecules may be expressed without requiring refolding procedures in vitro after expression of denatured protein.

Improved folding may also help improve expression in mammalian cells.

-22- Improvements in expression levels will meet an important need for production of antibody-based therapeutics. High costs of goods have been a significant limitation for commercialization of products based on antibody binding sites where molecules may be active in vivo but require high levels of protein for therapeutic efficacy (sometimes exceeding 1 gram per patient). In fact, it is likely that high costs associated with expression currently represent the greatest barrier to success with antibody based products.

For recombinant production, a contiguous polynucleotide sequence containing coding sequences of multiple binding partners is inserted into an appropriate expression S"vehicle, a vector which contains the necessary elements for the transcription and translation of the inserted coding sequence, or in the case of an RNA viral vector, the necessary elements for replication and translation. The expression vehicle is then transfected into a suitable target cell which will express the encoded product. Depending on the expression system used, the expressed product is then isolated by procedures well-established in the art. Methods for recombinant protein and peptide production are well known in the art (see, Maniatis et al, 1989, Molecular Cloning A Laboratory Manual, Cold Spring Harbor Laboratory, and Ausubel et al., 1989, Current Protocols in Molecular Biology, Greene Publishing Associates and Wiley Interscience, The published crystal structure (Desmyter et al., 1996, Nat. Struct. Biol. 3:803- .*i 811) of a camelid VHH molecule indicates that the amino and carboxy termini of the VHH molecule are exposed to solvent on different sides of the molecule, the desired configuration for constructing multispecific fusion proteins. Multispecific VHH molecules are constructed by linking the cDNAs encoding one VHH to a second VHH through a spacer cDNA encoding an amino acid linker molecule. Adding another VH and linker to this bispecific, and continuing this process to gradually build an array of binding sites, results in a multispecific molecule. By including the appropriate unique restriction sites at each end of the VHH and linker cassettes, the molecules can be assembled in any plasmid vector with the appropriate restriction site polylinker for such sequential insertions. Alternatively, a new polylinker may be constructed in an existing plasmid that encodes several restriction sites interspersed with DNA encoding the amino 23 acid linkers for at least two of the junctions between VHH molecules. Some of the linkers include (gly 4 ser) 3 (gly 3 ser 2 3 other types of combinations of glycine and serine (glyxsery)z, hinge like linkers similar to those attached to the llama VHH domains (including some or all portion of the region between amino acids 146-170) which include sequences encoding varying lengths of alternating PQ motifs (usually 4-6) as part of the linker, linkers with more charged residues to improve hydrophilicity of the multispecific molecule, or linkers encoding small epitopes such as molecular tags for detection, identification, and purification of the molecules.

A preferred embodiment of the present invention includes PCR amplification of VHH molecules targeted to CD80, CD86, and CD40, each with unique, rare restriction sites at the ends of the cDNAs. An expression plasmid is created with a polylinker into which complementary oligonucleotides encoding two or more of the amino acid linkers outlined above have been inserted and annealed. At each end of the inserted oligonucleotides, the restriction site matches that found on the amino or carboxy terminus or 3' end) of one of the VHH cassetter. Multispecific molecules can then be assembled by successive digestion and ligation of the oligonucleotide-polylinker plasmid with the individual VHH cassettes.

A variety of host-expression vector systems may be utilized to express a multispecific molecule. These include, but are not limited to, microorganisms such as bacteria transformed with recombinant bacteriophage DNA or plasmid DNA expression vectors containing an appropriate coding sequence; yeast or filamentous fungi transformed with recombinant yeast or fungi expression vectors containing an appropriate coding sequence; insect cell systems infected with recombinant virus expression vectors baculovirus) containing an appropriate coding sequence; plant cell systems infected with recombinant virus expression vectors cauliflower mosaic virus or tobacco mosaic virus) or transformed with recombinant plasmid expression vectors Ti plasmid) containing an appropriate coding sequence; or animal cell systems.

The expression elements of the expression systems vary in their strength and specificities. Depending on the host/vector system utilized, any of a number of suitable transcription and translation elements, including constitutive and inducible promoters, -24may be used in the expression vector. For example, when cloning in bacterial systems, inducible promoters such as pL of bacteriophage plac, ptrp, ptac (ptrp-lac hybrid promoter) and the like may be used; when cloning in insect cell systems, promoters such as the baculovirus polyhedron promoter may be used; when cloning in plant cell systems, promoters derived from the genome of plant cells heat shock promoters; the promoter for the small subunit of RUBISCO; the promoter for the chlorophyll a/b binding protein) or from plant viruses the 35S RNA promoter of CaMV; the coat protein promoter of TMV) may be used; when cloning in mammalian cell systems, S"promoters derived from the genome of mammalian cells metallothionein promoter) or from mammalian viruses the adenovirus late promoter; the vaccinia virus 7.5 K promoter; cytomegalovirus (CMV) promoter) may be used; when generating cell lines that contain multiple copies of expression product, SV40-, BPV- and EBV-based vectors may be used with an appropriate selectable marker.

In cases where plant expression vectors are used, the expression of sequences encoding a multispecific molecule may be driven by any of a number of promoters. For example, viral promoters such as the 35S RNA and 19S RNA promoters of CaMV (Brisson el al., 1984, Nature 310:511-514), or the coat protein promoter of TMV (Takamatsu et al., 1987, EMBO J. 6:307-311) may be used; alternatively, plant promoters such as the small subunit of RUBISCO (Coruzzi et al., 1984, EMBO J.

3:1671-1680; Broglie et al., 1984, Science 224:838-843) or heat shock promoters, e.g., soybean hspl7.5-E or hspl7.3-B (Gurley etal., 1986, Mol. Cell. Biol. 6:559-565) may be used. These constructs can be introduced into plant cells using Ti plasmids, Ri plasmids, plant virus vectors, direct DNA transformation, microinjection, electroporation, etc. For reviews of such techniques see, Weissbach Weissbach, 1988, Methods for Plant Molecular Biology, Academic Press, NY, Section VIII, pp. 421- 463; and Grierson Corey, 1988, Plant Molecular Biology, 2d Ed., Blackie, London, Ch. 7-9.

In one insect expression system that may be used to produce the molecules of the invention, Autographa californica nuclear polyhidrosis virus (AcNPV) is used as a vector to express the foreign genes. The virus grows in Spodopterafrugiperda cells. A coding sequence may be cloned into non-essential regions (for example the polyhedron gene) of the virus and placed under control of an AcNPV promoter (for example, the polyhedron promoter). Successful insertion of a coding sequence will result in inactivation of the polyhedron gene and production of non-occluded recombinant virus virus lacking the proteinaceous coat coded for by the polyhedron gene). These recombinant viruses are then used to infect Spodopterafrugiperda cells in which the inserted gene is expressed. see Smith et al., 1983, J. Virol. 46:584; Smith, U.S.

Patent No. 4,215,051). Further examples of this expression system may be found in Current Protocols in Molecular Biology, Vol. 2, Ausubel et al., eds., Greene Publish.

Assoc. Wiley Interscience.

In mammalian host cells, a number of viral based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, a coding *i sequence may be ligated to an adenovirus transcription/translation control complex, e.g., the late promoter and tripartite leader sequence. This chimeric gene may then be inserted in the adenovirus genome by in vitro or in vivo recombination. Insertion in a S non-essential region of the viral genome region El or E3) will result in a recombinant virus that is viable and capable of expressing peptide in infected hosts.

S. See Logan Shenk, 1984, Proc. Natl. Acad. Sci. (USA) 81:3655-3659).

Alternatively, the vaccinia 7.5 K promoter may be used, (see, Mackett et al., 1982, Proc. Natl. Acad. Sci. (USA) 79:7415-7419; Mackett et al., 1984, J. Virol. 49:857-864; Panicali et al., 1982, Proc. Natl. Acad. Sci. 79:4927-4931).

A multispecific molecule can be purified by art-known techniques such as high performance liquid chromatography, ion exchange chromatography, gel electrophoresis, affinity chromatography and the like. The actual conditions used to purify a particular molecule will depend, in part, on factors such as net charge, hydrophobicity, hydrophilicity, etc., and will be apparent to those having skill in the art.

For affinity chromatography purification, any antibody which specifically binds the molecule may be used. For the production of antibodies, various host animals, including but not limited to rabbits, mice, rats, etc., may be immunized by injection with a multispecific molecule or a portion thereof. The molecule or a peptide thereof may be attached to a suitable carrier, such as BSA, by means of a side chain functional group or linkers attached to a side chain functional group. Various adjuvants may be used to -26increase the immunological response, depending on the host species, including but not limited to Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, dinitrophenol, and potentially useful human adjuvants such as BCG (bacilli Calmette-Guerin) and Corynebacterium parvum.

5.4. USES OF ACTIVATED LYMPHOCYTES FOLLOWING MULTIPLE SURFACE ANTIGEN

AGGREGATION

Lymphocytes are activated in culture by aggregation of multiple surface antigens in accordance with the method of the invention. The activated cells may be used in adoptive therapy of infectious diseases, particularly viral infections such as AIDS, and cancer. Activated cells may secrete cytokines or have other effector mechanisms that suppress responses to autoantigens or transplants, and may therefore be useful for treatment of autoimmune diseases and transplant rejection. In addition, multispecific molecules that aggregate multiple antigens may be administered directly into a subject to augment immune responses against an infectious agent such as a virus or against tumor cells. Furthermore, such molecules may deliver an apoptotic signal to T and B cell tumors to directly induce tumor destruction. Alternatively, multispecific molecules may be used as inhibitors of immune responses by interfering with antigen presentation or T cell/B cell interactions. These molecules are useful for treatment of autoimmunity, and hypersensitivity as well as prevention of transplantation rejections.

5.4.1. FORMULATION AND ROUTE OF ADMINISTRATION A multispecific molecule of the invention may be administered to a subject per se or in the form of a pharmaceutical composition. Pharmaceutical compositions comprising a multispecific molecule of the invention may be manufactured by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes. Pharmaceutical compositions may be formulated in conventional manner using one or more physiologically acceptable 27 carriers, diluents, excipients or auxiliaries which facilitate processing of the active ingredient into preparations which can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen.

For topical administration, a multispecific molecule of the invention may be formulated as solutions, gels, ointments, creams, suspensions, etc. as are well-known in the art.

Systemic formulations include those designed for administration by injection, e.g. subcutaneous, intravenous, intramuscular, intrathecal or intraperitoneal injection, as well as those designed for transdermal, transmucosal, oral or pulmonary administration such as aerosol, inhaler and nebulizer.

For injection, a multispecific molecule of the invention may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks's solution, Ringer's solution, or physiological saline buffer. The solution may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.

Alternatively, a multispecific molecule may be in powder form for constitution with a suitable vehicle, sterile pyrogen-free water, before use.

For transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.

For oral administration, a multispecific molecule can be readily formulated by' combining with pharmaceutically acceptable carriers well known in the art. Such carriers enable a multispecific molecule of the invention to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a patient to be treated. For oral solid formulations such as, for example, powders, capsules and tablets, suitable excipients include fillers such as sugars, such as lactose, sucrose, mannitol and sorbitol; cellulose preparations such as maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidone (PVP); granulating agents; and binding agents. If desired, disintegrating agents may be added, such as the cross-linked polyvinylpyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.

-28 If desired, solid dosage forms may be sugar-coated or enteric-coated using standard techniques.

For oral liquid preparations such as, for example, suspensions, elixirs and solutions, suitable carriers, excipients or diluents include water, glycols, oils, alcohols, etc. Additionally, flavoring agents, preservatives, coloring agents and the like may be added.

For buccal administration, a multispecific molecule may take the form of tablets, lozenges, etc. formulated in conventional manner.

For administration by inhalation, a multispecific molecule for use according to the present invention are conveniently delivered in the form of an aerosol spray from pressurized packs or a nebulizer, with the use of a suitable propellant, e.g., *0 dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of e.g. gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.

:A multispecific molecule may also be formulated in rectal or vaginal compositions such as suppositories or retention enemas, e.g, containing conventional suppository bases such as cocoa butter or other glycerides.

In addition to the formulations described previously, a multispecific molecule may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, a multispecific molecule may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.

Alternatively, other pharmaceutical delivery systems may be employed.

Liposomes and emulsions are well known examples of delivery vehicles that may be used to deliver a multispecific molecule of the invention. Certain organic solvents such as dimethylsulfoxide also may be employed, although usually at the cost of greater toxicity. Additionally, a multispecific molecule may be delivered using a sustained- 29 release system, such as semipermeable matrices of solid polymers containing the therapeutic agent. Various sustained-release materials have been established and are well known by those skilled in the art. Sustained-release capsules may, depending on their chemical nature, release a multispecific molecule for a few weeks up to over 100 days. Depending on the chemical nature and the biological stability of the therapeutic reagent, additional strategies for protein stabilization may be employed.

As a multispecific molecule of the invention may contain charged side chains or termini, they may be included in any of the above-described formulations as the free acids or bases or as pharmaceutically acceptable salts. Pharmaceutically acceptable salts •are those salts which substantially retain the biologic activity of the free bases and which are prepared by reaction with inorganic acids. Pharmaceutical salts tend to be more S" soluble in aqueous and other protic solvents than are the corresponding free base forms.

ooooo 5.4.2. EFFECTIVE DOSAGES A multispecific mnolecule of the invention will generally be used in an amount effective to achieve the intended purpose. For use to activate or suppress an immune response mediated T cells and/or B cells, a multispecific molecule of the invention, or pharmaceutical compositions thereof, are administered or applied in a therapeutically effective amount. By therapeutically effective amount is meant an amount effective to S "ameliorate or prevent the symptoms, or prolong the survival of, the patient being treated.

Determination of a therapeutically effective amount is well within the capabilities of those skilled in the art, especially in light of the detailed disclosure provided herein.

For systemic administration, a therapeutically effective dose can be estimated initially from in vitro assays. For example, a dose can be formulated in animal models to achieve a circulating concentration range that includes the IC,5 0 as determined in cell culture. Such information can be used to more accurately determine useful doses in humans.

Initial dosages can also be estimated from in vivo data, animal models, using techniques that are well known in the art. One having ordinary skill in the art could readily optimize administration to humans based on animal data.

Dosage amount and interval may be adjusted individually to provide plasma levels of a multispecific molecule which are sufficient to maintain therapeutic effect.

Usual patient dosages for administration by injection range from about 0.1 to mg/kg/day, preferably from about 0.5 to 1 mg/kg/day. Therapeutically effective serum levels may be achieved by administering multiple doses each day.

In cases of local administration or selective uptake, the effective local concentration of a multispecific molecule may not be related to plasma concentration.

One having skill in the art will be able to optimize therapeutically effective local dosages without undue experimentation.

The amount of a molecule administered will, of course, be dependent on the subject being treated, on the subject's weight, the severity of the affliction, the manner of administration and the judgment of the prescribing physician.

i The therapy may be repeated intermittently while symptoms are detectable or even when they are not detectable. The therapy may be provided alone or in combination with other drugs.

5.4.3. TOXICITY Preferably, a therapeutically effective dose of a multispecific molecule described *herein will provide therapeutic benefit without causing substantial toxicity.

Toxicity of a multispecific molecule described herein can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, by determining the LD 50 (the dose lethal to 50% of the population) or the LDo (the dose lethal to 100% of the population). The dose ratio between toxic and therapeutic effect is the therapeutic index. Molecules which exhibit high therapeutic indices are preferred.

The data obtained from these cell culture assays and animal studies can be used in formulating a dosage range that is not toxic for use in human. The dosage of a multispecific molecule described herein lies preferably within a range of circulating concentrations that include the effective dose with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. The exact formulation, route of administration and dosage can -31 be chosen by the individual physician in view of the patient's condition. (See, Fingl et al., 1975, In: The Pharmacological Basis of Therapeutics, Ch.l, p.1).

TRANSGENIC ANIMALS THAT EXPRESS LLAMA VHH The VHH gene sequences isolated by the methods disclosed herein can be expressed in animals by transgenic technology to create founder animals that express llama VHH (United States Patent No. 5,545,806; W098/24893). Animals of any species, including, but not limited to, mice, rats, rabbits, guinea pigs, pigs, micro-pigs, goats, sheep, and non-human primates, baboons, monkeys, and chimpanzees may be used to generate llama VHH-expressing transgenic animals. The term "transgenic," as used herein, refers to animals expressing coding sequences from a different species mice expressing llama gene sequences).

Any technique known in the art may be used to introduce VHH transgenes into animals to produce the founder lines of transgenic animals. Such techniques include, but are not limited to, pronuclear microinjection (Hoppe and Wagner, 1989, U.S. Patent No.

4,873,191); retrovirus-mediated gene transfer into germ lines (Van der Putten, et al., 1985, Proc. Natl. Acad. Sci., USA 82:6148-6152); gene targeting in embryonic stem cells (Thompson, et al., 1989, Cell 56:313-321); electroporation of embryos (Lo, 1983, Mol. Cell. Biol. 3:1803-1814); and sperm-mediated gene transfer (Lavitrano et al., 1989, Cell 57:717-723) (see Gordon, 1989, Transgenic Animals, Intl. Rev. Cytol. 115, 171- 229). Any technique known in the art may be used to produce transgenic animal clones containing VHH transgenes, for example, nuclear transfer into enucleated oocytes of nuclei from cultured embryonic, fetal or adult cells induced to quiescence (Campbell, et al., 1996, Nature 380:64-66; Wilmut, et al., Nature 385:810-813).

The present invention provides for transgenic animals that carry the VHH transgenes in all their cells, as well as animals that carry the transgenes in some, but not all their cells, mosaic animals. The VHH may be integrated as individual gene segments or in concatamers, head-to-head tandems or head-to-tail tandems. The VHH transgenes may also be selectively introduced into a particular cell type such as lymphocytes by following, for example, the teaching of Lasko et al. (1992, Proc. Natl.

Acad. Sci. USA 89:6232-6236). The regulatory sequences required for such a cell-type -32specific activation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art. When it is desired that the transgenes be integrated into the chromosomal site of the endogenous variable region genes, gene targeting is preferred. Briefly, when such a technique is to be utilized, vectors containing some nucleotide sequences homologous to the endogenous genes are designed for the purpose of integrating, via homologous recombination with chromosomal sequences, into and disrupting the function of the nucleotide sequences of the endogenous genes. The transgenes may also be selectively introduced into a particular cell type, thus inactivating the endogenous genes in only that cell type, by following, for example, the teaching of Gu, et al. (1994, Science 265: 103-106). The regulatory sequences required for such a cell-type specific inactivation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art.

*i Once transgenic animals have been generated, the expression of the llama V,, may be assayed utilizing standard techniques. Initial screening may be accomplished by Southern blot analysis or PCR techniques to analyze animal tissues to assay whether •integration of the VH has taken place. The level ofmRNA expression of the VHH in the tissues of the transgenic animals following immunization of an antigen may also be assessed using techniques that include, but are not limited to, Northern blot analysis of tissue samples obtained from the animal, in situ hybridization analysis, and RT-PCR.

Samples of VH-expressing tissue, may also be evaluated immunocytochemically using antibodies specific for llama variable region epitopes.

Various procedures known in the art may be used for the production of Vm to any antigen by immunizing transgenic animals with an antigen. Mice are preferred because of ease of handling and the availability of reagents. Such antibodies include, but are not limited, to polyclonal, monoclonal, chimeric, humanized, single chain, antiidiotypic, antigen-binding antibody fragments and fragments produced by a variable region expression library.

Various adjuvants may be used to increase the immunological response, depending on the host species, including but not limited to Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet 33 hemocyanin, dinitrophenol, and potentially useful human adjuvants such as BCG (bacilli Calmette-Guerin) and Corynebacterium parvum.

MAbs may be prepared by using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include but are not limited to the hybridoma technique originally described by Kohler and Milstein, (Nature, 1975,256:495-497). Such antibodies may be heavy chain-only antibodies and of any immunoglobulin class including, but not limited to, IgG, IgM, IgE, IgA, IgD and any subclass thereof.

The invention having been described, the following examples are offered by way of illustration and not limitation.

o* 6. EXAMPLE: IMMOBILIZED ANTIBODIES SPECIFIC o* e FOR THREE T CELL SURFACE ANTIGENS ENHANCED HUMAN T CELL PROLIFERATION 6.1. MATERIALS AND METHODS 6.1.1. STIMULATION OF HUMAN T CELL PROLIFERATION Mononuclear cells were isolated from human peripheral blood by centrifugation S.on "FICOLL". Monocytes were depleted by two rounds of adherence to plastic. The mononuclear cells were then stimulated in 96-well Costar flat-bottom microtiter plates at 50,000 cells per well containing immobilized antibodies. The antibodies were immobilized by incubating purified antibody mixtures in phosphate buffered saline (PBS) in the wells at 100 pl/well for 3 hr at 37 0 C, followed by washing away of the unbound antibodies from the wells prior to addition of cells. Antibody concentrations were 10 pg/ml of anti-CD3, 10 pg/ml of anti-CD2, and varying concentrations of a third antibody as indicated. Proliferation was measured in quadruplicate wells by incorporation of H-thymidine during the last 18 hours of a 4 day culture. Means are shown, and standard errors are less than 15% of the mean at each point.

-34- 6.1.2. ANTI-T CELL ANTIBODIES MAb anti-CD3, OKT3, was obtained from ATCC (ATCC CRL-8001). MAb anti-CD28, B-T3, was purchased from Diaclone (Besancon, France). MAb anti-CD2, 9.6, and anti-CD28 antibody, 9.3, were provided by John Hansen (FHCRC, Seattle, WA). Anti-CD4 OKT4, was obtained from the ATCC (ATCC CRL-8002). MAb anti- 10.2, was provided by John Hansen (FHCRC, Seattle, WA). Control mAb was L6.

mAb is described by Clark and Ledbetter (1986, Proc. Natl. Acad. Sci.

U.S.A. 83:4494-4498). Anti-CD18 mAb is described by Beatly et al. (1983, J. Immunol.

131:2913-2918).

S* 6.1.3. T CELL SUBSET SEPARATION T cells were isolated from peripheral blood by centrifugation on "FICOLL", followed by separation into CD4' or CD8' subsets by depletion ofmonocytes, B cells, NK cells, and either CD4 or CD8 cells. Cell depletion was performed using mAbs to CD14, CD20, CD1 Ib, and CD8 or CD4 followed by removal of antibody-bound cells S• using magnetic beads coated with anti-mouse IgG. CD4' or CD8* T cells were pure after the depletion step when analyzed by flow cytometry. Cells were cultured in Santibody-coated microtiter plates at 5 X 104 for 4 days, and proliferation was measured by incorporation of 3 H-thymidine for the final 12 hours of culture. Microtiter plates.

contained immobilized antibodies as indicated, including the control, nonbinding antibody in some wells to equalize the total protein concentration for immobilization.

Antibodies were immobilized by incubation at 10 yg/m each for 18 hr at 37 0

C,

followed by removal of unbound protein by extensive washing.

6.1.4. ANTI-TCR VARIABLE REGION ANTIBODIES MAbs specific for TCR V38 (Pharmingen 3313 1A), V39 (Pharmingen 3313 IB), Vpl4 (Coulter Im. 1557), and Vp20 (Coulter Im. 1561) were immobilized on culture plates using a two-step procedure. Purified goat anti-mouse (Capel) antibody was immobilized first, followed by washing and blocking before addition of the anti-Vp mAb plus anti-CD28. Cell growth was observed, and after 9 days, the proliferating cells were transferred to new culture plates containing 5 U/mL interleukin-2 Inc., Minneapolis, MN). Five days later, on day 14, the cells were analyzed by flow cytometry for expression of TCR Vi specificity using a secondary fluorescein-conjugated antimouse IgG reagent (Biosource).

6.1.5. ANTIBODY COUPLING TO BEADS FOR CELL

STIMULATION

A suspension of 2.8 mQ "DYNAL" beads (Oslo, Norway), M-450 tosyl activated, at 4x 108 beads/mQ were washed three times, each with four mQ of 0.1 M sodium borate, using a magnet for buffer removal. The beads were then suspended in 1.5 mQ of borate buffer. To 200 vp (1.8x10 8 beads) of bead suspension was added a mixture of 140 p borate buffer, 30 pg of a given antibody to be coupled, and PBS. The volume of added PBS was adjusted such that the final volume of the reaction mixture was 400 pe.

All possible combinations of antibodies to CD3 (OKT-3), CD28 and CD2 (9.6) were coupled. The antibodies were allowed to react with the beads for approximately hr at 37 0 C on a rotator. This was followed by removal of unreacted antibody with a magnet. The bead preparations were then washed three times with 1 mQ PBS containing 0.1% (wt:vol) sodium azide and three times with PBS containing 3% (vol:vol) human serum, 5 mM EDTA, and 0.1% (wt:vol) sodium azide (storage buffer). The last of the three washes in storage buffer was done for 30 minutes at ambient temperature on a rotator. All the bead preparations were then incubated with storage buffer for approximately 31 hr at 4 0 C on a rotator. This was followed by re-suspension of each of Sthe preparations in 1.0 mQ storage buffer.

Peripheral blood lymphocytes were isolated by density centrifugation. The lymphocytes were adhered to plastic in RPMI with 2% FCS. Cells were pelleted and plated in 96-well flat-bottom plates at a density of 2.5 x 10'/ml. Dynal beads conjugated with mAbs were then plated with the cells at a ratio of 3 beads: 1 cell. Cells were incubated at 37°C and 5% CO, for 5 days. One pCi/well of 3 H-thymidine was then added to the wells and incubated overnight. Cultures were harvested on a glass filter mat and cpm measured.

-36- 6.2. RESULTS Human T cells were isolated from peripheral blood of normal donors and stimulated in vitro with immobilized mAbs directed to three T cell surface antigens.

Antibodies specific for CD2 and CD3 plus a third antibody, such as anti-CD28, anti-CD4 or anti-CD5, were co-immobilized by adsorption on the surface of culture plates, followed by incubation with T cells in culture media. T cell proliferation was assayed as a measure ofT cell activation. The combination of three immobilized antibodies enhanced T cell proliferation when compared with the combined use of immobilized anti-CD2, anti-CD3 antibodies and a third control antibody, L6, specific for an antigen not expressed by T cells (Figure In particular, the combination of anti-CD2, anti-CD3 and anti-CD28 produced the highest level ofT cell proliferation at all concentrations tested. Three immobilized antibodies induced greater cellular proliferation than the same antibodies presented in solution or two immobilized antibodies plus a third antibody in solution. Co-immobilized anti-CD3 and anti-CD28 plus anti-CD1S mAbs also induced greater T cell proliferation than the combination of two of the three antibodies.

Additionally, co-immobilized anti-CD3, anti-CD28 and anti-CD40 mAbs enhanced proliferation of purified T cells (Figure It is noted that CD40 is expressed by activated T cells as well as antigen presenting cells. Therefore, aggregation of three T cell surface antigens by co-immobilized antibodies enhanced T cell activation.

Immobilized antibodies may be used to expand T cell and B cell numbers in culture as well as inducing cellular differentiation. The activated cells can be separated from the immobilized antibodies more easily than from antibodies added in solution so that injection of antibodies bound to cells into a recipient can be minimized when the cells are harvested for use in adoptive therapy.

When purified CD4' or CD8' T cells were incubated with immobilized anti-CD3 antibody, cellular proliferation was minimal, whether the antibody was immobilized alone at 30 yg/mQ, or immobilized together with control antibody L20 at concentrations of 10 /ag/mQ anti-CD3 plus 20 ,g/mQ L20 (Figure However, when anti-CD28 mAb was immobilized with anti-CD3, an increase in proliferation of both CD4' and CD8* T cells was observed, and such effects were not further enhanced by addition of more anti- CD28 mAb (Figure Similarly, co-immobilized anti-CD2 mAb and anti-CD3 mAb -37 increased the proliferation ofCD4* and CD8 T cells above the level induced by anti- CD3 alone. When both anti-CD2 and anti-CD28 were added to anti-CD3 during the antibody immobilization step, there was a further dramatic increase in proliferation of CD4' T cells, whereas proliferation of CD8' cells was not enhanced above that induced by anti-CD3 plus anti-CD28 or by anti-CD3 plus anti-CD2 (Figure These results show that the combination of co-immobilized anti-CD3, anti-CD28 and anti-CD2 antibodies enhanced proliferation of CD4' T cells over the combination of coimmobilized anti-CD3 and anti-CD28 or the combination of anti-CD3 and anti-CD2. In total T cell stimulation, anti-CD3, anti-CD28 and anti-CD2 combination is expected to induce greater amounts of lymphokine production by CD4' T cells, which in turn stimulate greater CD8' T cell activation. In that connection, co-immobilized antibodies stimulate distinct cytokine profiles by activated T cells, depending on which specific .combination of three or more antibodies is used. Such activated T cells may be cocultured with other cell types in vitro such as monocytes or dendritic cells to promote their growth or differentiation in the absence of exogenous cytokines.

In addition, Figure 5A and 5B shows that 3 H-thymidine incorporation measurement ofT cell proliferation correlated directly with cell growth after stimulation with immobilized antibodies. Proliferation of purified CD4' T cells was measured at day 7 with a 12 hr pulse of 3 H-thymidine, while cell number was measured on day 8 by direct cell counting with a hemocytometer. Such findings indicate that measurement ofT cell proliferation by 3 H-thymidine uptake is directly reflective of the ability of coimmobilized anti-CD2, anti-CD3 and anti-CD28 antibodies to expand T cell numbers in cultures.

In order to test the ability of the antibodies immobilized on another form of solid support in T cell activation, mAbs were co-immobilized on "DYNAL" beads and incubated with human T cells. Figure 6 shows that the combination of anti-CD3, anti- CD2 and anti-CD28 antibodies co-immobilized on beads consistently induced the highest level ofT cell proliferation from all patients tested as compared to anti-CD3 alone or two antibody combinations. Thus, co-immobilization of antibodies on beads produces superior activation ofT cells. Furthermore, Figure 7A and 7B demonstrates that co-immobilization of antibodies on the same beads produced higher levels of T cell -38 proliferation than a mixture of beads with separately immobilized antibodies, indicating that aggregation of multiple surface molecules on T cells is achieved optimally by positioning the antibodies in close proximity to each other. In that connection, Figure 8 shows that anti-CD2 immobilized on separate beads or added in solution inhibited T cell proliferation stimulated by anti-CD3 and anti-CD28 co-immobilized on the same beads.

In another experiment, T cells were selectively stimulated by anti-TCR variable region antibodies co-immobilized on culture plates with anti-CD28, followed by analysis of Vp specificity of the cultured cells. The cells stimulated with co-immobilized anti- TCR Vp8 and anti-CD28 were 72% positive for expression of VP8, but did not express Vp9, VP14, or Vp20 above the level detected by control anti-mouse IgG second step reagent alone (Figure 9B, 9D, and 9F). In contrast, the cells stimulated with coimmobilized anti-TCR Vi9 and anti-CD28 from the same donor sample did not react with the anti-Vp8, anti-Vpl4, or anti-VP20 antibodies, but reacted significantly positive) with the anti-VP9 mAb (Figure 9A, 9C and 9E). The cells from this donor analyzed before antibody stimulation showed that expression of each of these V3 specificities was less that These data show that very small subpopulations of T cells can be selectively expanded using mAbs specific for individual TCR V3 epitopes and an anti-CD28 mAb co-immobilized on a solid surface. Since TCR VP usage shows a significant correlation with antigen-specific reactivity ofT cells, and TCR V3 usage can be highly skewed in patients with autoimmune disease and cancer, it is likely that antigen-specific T cells or T cells highly enriched for a specific antigen recognition can be selectively expanded using the appropriate VP mAb immobilized with an anti-CD28 mAb. Furthermore, immobilization of a third mAb to an additional T cell antigen, such as CD2, CD 150, or ICOS will further enhance the selective expansion ofT cells expressing a specific Vp. Antibodies to two or more VP chains may also be used together with anti- CD28 and additional mAbs to expand T cells expressing the desired VP polypeptide chains without expanding the other T cell subsets. Moreover, T cells expressing yb TCR may also be selectively expanded by a mAb to y8 heterodimer co-immobilized with other antibodies. Any antibody reactive with a component of the TCR/CD3 complex, -39 including any CD3 polypeptide chain or epitopes of the TCR alphalbeta or gamma/delta dimers such as the CDRs may be used for the practice of the invention.

7. EXAMPLE: LLAMA B CELLS EXPRESSED CD40 AND PRODUCED HEAVY CHAIN-ONLY ANTIBODIES THAT BOUND HUMAN CELL SURFACE

ANTIGENS

7.1. MATERIALS AND METHODS 7.1.1. IMMUNIZATION OF LLAMAS Llama llama were obtained from JJJ Farms (Redmond, WA) and immunized :intraperitoneally with human cells in PBS and Freund's complete adjuvant, followed by least 3 rounds of boosting with the same cells in Freund's incomplete adjuvant. The .cell types used for immunization included normal unstimulated or activated human "'•°."peripheral blood lymphocytes (PBL), T cellI lines such as Jurkat and HPB3-ALL, B cellI lines such as Daudi and Ramos or EBV-transformed line CESS. Llamas were also immunized with 100-500 pag purified fusion proteins in PBS mixed with adjuvant as •,0described above for the cells. Animals were bled 4-7 days after each boost to determine if sera contained antibodies reactive with the target cells. Large bleeds (200 ml) were o• °performed after the third boost or after later boosts, depending on the antibody response of the animal. Animals were bled by venipuncture of the jugular vein and whole blood was treated with citrate anticoagulant.

7.1.2. PREPARATION OF LLAMA PERIPHERAL BLOOD Llama whole blood (200 ml) was centrifuged at 900 rpm for 20 minutes and the upper layer of cells containing peripheral blood mononuclear cells was aspirated to a secondary tube. This fraction was then diluted 1 1 in PBS and 30 ml were loaded onto ml cushions of Lymphocyte Separation Media (LSM, Organon Teknika). Buffy coats were fractionated by centrifugation at 2000 rpm for 20 minutes in a Sorvall tabletop centifuge and isolated by aspiration from the serum./LSM interface. Cells were washed three times in PBS or serum free RPMI, spun at 1200-1400 rpm for 10 minutes, and counted after the final spin. The appropriate number of cells was aliquoted to fresh centrifuge tubes for the final spin. The final cell pellets were snap frozen without liquid in dry ice-ethanol baths at 10' cells/tube and placed at -70 0 C until mRNA isolation.

Alternatively, cells were resuspended and cultured overnight in RPMI/10% fetal calf serum at a cell density of 106 cells/ml for use in binding assays or functional studies in vitro. Cells were also frozen in aliquots of 2 x 10 7 cells in serum/10% DMSO for use in future functional assays.

7.1.3. CELL STAINING AND FLOW CYTOMETRY PBL from L. llama were isolated by centrifugation on LSM and the cells were stained with an anti-CD40 mAb, G28-5, Patent No. 5,182,368), an anti-llama immunoglobulin and an anti-light chain antibody. The anti-CD40 antibody (G28-5) was labeled with biotin, and its binding was detected with phycoerythrin-conjugated strepavidin. The anti-llama Ig was directly labeled with fluorescein. The anti-light chain staining was performed using fluorescein-conjugated anti-human kappa plus anti-human lambda reagents from Caltag (Burlingame, CA). Cell staining was analyzed by a FACSCAN flow cytometer.

7.1.4. PROLIFERATION OF LLAMA LYMPHOCYTES PBL from L. llama were isolated by centrifugation on LSM. The lymphocytes were stimulated with phorbol-12-myristic acid (PMA) (10 ng/ml), an anti-CD40 mAb (G28-5 at I ig/ml), CD86-expressing Chinese hamster ovary (CHO) cells, control CHO cells or combinations of the aforementioned reagents. CHO cells were irradiated prior to the assay to prevent CHO cell proliferation. Lymphocyte proliferation was measured in quadruplicate wells of a microtiter plate containing 50,000 lymphocytes each by incorporation of 3 H-thymidine during the last 12 hr of a three day culture period. Means are shown from lymphocyte proliferation results from two different llamas.

7.1.5. PURIFICATION OF LLAMA ANTIBODIES Serum from a llama immunized with multiple injections ofJurkat T cells was fractionated by a multi-step procedure into conventional and heavy chain-only IgG isotypes. Serum was first bound to Protein A, eluted, and then separated by DEAE ion exchange chromatography. The Protein A eluate was separately fractionated by binding -41 to Protein G, followed by elution at pH 2.7 or at pH 3.5. Fractions were analyzed by SDS-PAGE after reduction.

7.2. RESULTS Isolated llama PBL were reacted with anti-CD40 and anti-Ig or anti-light chain antibodies, and analyzed by flow cytometry. Figure 10A and 10B shows that a population of llama peripheral blood cells reacted with an anti-human CD40 antibody.

Two color staining further demonstrates that all CD40' cells expressed surface Ig, indicating that these cells were antibody-producing B cells (Figure 10E and 1 OF).

However, only a portion of the CD40' cells expressed detectable light chain (Figure and 10D). These results indicate that llama B cells express conventional antibodies composed of heavy and light chains, and heavy chain-only antibodies devoid of light chains. Thus, llama B cells expressing heavy chain-only antibodies can be separated Sfrom other B cells by their reactivity with anti-CD40 and lack of reactivity with anti-light chain reagents.

PBL from two llamas were isolated and stimulated with different reagents, followed by measurement of cellular proliferation. Anti-CD40 antibody stimulated llama B cell proliferation, which was further enhanced by PMA (Figure 11). While CD86 (or B7.2)-expressing CHO cells alone did not induce L. llama B cell proliferation, its combined use with PMA induced significant proliferation (Figure 11). stimulation may also induce llama B cell differentiation and Ig affinity maturation in culture. Therefore, CD40 stimulation may be used to selectively expand llama B cells producing heavy chain-only antibodies to facilitate the isolation of these antibodies and their specific VH regions. In addition, an anti-CD40 antibody may be injected into llamas to stimulate B cells in vivo in order to enhance the number of B cells producing VHH. Cells expressing specific variable regions may be isolated by a variety of methods, including rosetting with specific antigen bound to red blood cells.

A llama was immunized with human T cells and its serum was fractionated to separate heavy chain-only antibodies from conventional antibodies composed of heavy and light chains. The purified antibody fractions were analyzed by SDS-PAGE. Figure 12 shows purified Ig isotypes, including IgGI D (DEAE flowthrough in lane IgGI G -42- (Protein G, pH 2.7 elution in lane IgG2 IgG3 (Protein G, pH 3.5 elution in lane 3), and IgG3 (Protein G flowthrough in lane The IgG2 and IgG3 isotypes (lanes 3 and 4) contained a heavy chain band without detectable light chain.

The heavy chain-only antibodies (IgG2 IgG3, and IgG3 fractions) were incubated with Jurkat T cells for detection of antibody binding to cell surface antigens.

Specific binding was detected using a fluorescein-conjugated anti-llama Ig or anti-light chain second step reagent, followed by analysis with a flow cytometer (Figure 13A-13H).

Negative controls were purified IgG isotypes at the same concentrations from an unimmunized llama. While the anti-light chain reagent detected binding of the IgGI fractions (Figure 13B and 13D) to the Jurkat cells, the IgG2 and IgG3 fractions which did not contain light chains were not detected with the anti-light chain reagent (Figure 13F and 13H). However, when Jurkat cells were stained with the heavy chain-only fractions and detected by an anti-Ig second step reagent, antibody binding to Jurkat cell surface antigens was observed (Figure 13E and 13G). It is concluded that llama antibodies devoid of light chain were generated against human cell surface antigens.

-43 8. EXAMPLE: CONSTRUCTION OF L. LLAMA VnH LIBRARIES AND CHARACTERIZATION OF LLAMA VnH

SEQUENCES

8.1. MATERIALS AND METHODS 8.1.1. ISOLATION OF LLAMA mRNA Llama PBL mRNA was prepared by a modification of the guanidiniumthiocyanate acid-phenol procedure of Chomczynski and Sacchi (1987, Anal. Biochem.

162:156-159). For 10' cells, 5-10 ml denaturing/lysis solution was added to prepare RNA. PolyA RNA was isolated using oligo dT cellulose, washed in 75% ethanol/DEPC treated water, recentrifuged, and resuspended in DEPC treated water.

8.1.2. REVERSE TRANSCRIPTION-POLYMERASE CHAIN REACTION (RT-PCR) cDNA was generated by random hexamer primed reverse transcription reactions using Superscript II reverse transcriptase (GIBCO-BRL). PCR reactions were performed using the following primer set: The forward primer was LVH5'-1, one of a battery of mers designed from anmiro-terminal sequencing of the VH protein, with the sequence 5'CTC GTG GAR TCT GGA GGA GG3' (SEQ ID No:47), while the reverse primer used was LVH3RS, a 44-mer designed from previously determined, existing camel and human VH sequences. The sequence 5'CGT CAT GTC GAC GGA TCC AAG CTT TGA GGA GAC GGT GACYTG GG3' (SEQ ID NO:48) annealed at the 3' end of the V, domain. PCR products were electrophoresed on a 6% acrylamide/0.5X TBE gel, and the bands visualized after ethidium bromide staining. DNA bands were isolated from 2% NuSieve GTG gels (FMC) and purified using Qiaex beads (QIAGEN) according to manufacturer's instructions. Purified DNA after PCR was ligated into the pT-Adv plasmid vector (Clontech, Palo Alto, CA), and transformed into E. coli TOPIOF' (Clontech). Once a representative sample of VH and VHH sequences was determined, new primers were designed to select for amplification of VH,-containing fragments with a fragment length distinct from V,-containing fragments based on the absence of the CH1 domain in VHH fragments. These fragments were then purified, cloned into the phage display vector XPDNT, and used as template in generating libraries of llama variable regions containing mostly VHH sequences.

-44- Additional methods for the cloning of llama VHH region sequences are as follows.

Llama IgG 2 -specific VHH regions were cloned from cDNA prepared from llama PBL and amplified by PCR using a human Vhl family-specific 5' primer and a 3' llama IgG, hinge region primer. The sequences of these primers were AGGTGCAGCTGGTGCAGTCTGG (SEQ ID NO: 49) and GGTTGTGGTTTTGGTGTCTTG (SEQ ID NO: 50), respectively.

In addition, llama IgG 2 -specific VHH regions were cloned from cDNA prepared from llama PBL and amplified by PCR using a human Vh2 family-specific 5' primer with a 3' llama IgG 2 hinge region primer. The sequences of these primers were CAGGTCAACTTAAAGGGAGTCTGG (SEQ ID NO: 51) and GGTTGTGGTTTTGGTGTCTTG (SEQ ID NO: 50), respectively.

Llama IgG 2 -specific VHH regions were also cloned from cDNA prepared from llama PBL and amplified by PCR using a human Vh4 family-specific 5 'primer with a 3' llama IgG, hinge region primer. The sequences of these primers were AGGTGCAGCTGCAGGAGTCGG (SEQ ID NO: 52) and GGTTGTGGTTTTGGTGTCTTG (SEQ ID NO: 50), respectively.

Llama VHH sequences from the amplifications were pooled and digested with Sac and BamHI, then inserted into the modified phage display vector XPDNT, creating gene III fusion cassettes. The VH library was transformed into E. coli XL1BLUE bacteria'by electroporation and plated to large NUNC bioassay dishes containing SB/amp/tet media.

Platings on serially diluted samples were also performed at this step to estimate transformation efficiency. Libraries were scraped into SB/amp/tet containing glycerol and frozen in 1-2 ml aliquots at -70 C. Libraries were amplified in liquid 2XYT/amp/tet glucose at 37 0 C for several hours, then infected with helper phage, plated to determine phage titer, and grown under selective conditions in media lacking glucose at 30 0 C overnight. The amplified phage were isolated from these cultures by centrifugation to pellet bacteria, followed by PEG precipitation of culture supernatants, and a second centrifugation to recover phage precipitates. A small aliquot of unprecipitated culture supernatant was also harvested prior to the addition of PEG/NaC1.

Precipitates were resuspended in 1/100 volume PBS/1%BSA and spun for several minutes at 2000-5000 RCF to pellet insoluble material. Phage stocks or supernatants

F

were preblocked by incubation in 10% nonfat milk/PBS for 1 hour on ice prior to panning against preblocked human antigen or cells. Many rounds of panning were precleared with untransfected or normal human cells or with irrelevant -Ig fusion protein to reduce the frequency of nonspecific binders. Preclearing and panning were performed by coincubating the blocked phage with antigen or cells for 1 hour on ice and centrifugation to pellet bound phage. For panning with -Ig fusion protein antigens, protein A sepharose was used to capture phage-antigen complexes prior to centrifugation. Bound cells or protein A sepharose were washed at least 6 times and as many as 12 times in 10% milk/PBS, PBS/1%BSA or PBS/blocker/0.05% Tween prior to S. elution. Elution of bound phage was performed by incubation in one of several different buffers, and incubation for 10 minutes at room temperature. Elution buffers included 0.1N HCI, pH 2.5 in PBS, 0.1 M citric acid pH 2.8, 0.5% NP-40 in PBS, or 100MM triethylamine. Cells/sepharose were pelleted and the supematant containing eluted phage aliquoted to fresh tubes. Eluates were neutralized in 1M Tris, pH 9.5, prior to infection of logarithmic XLIBLUE cells. After infection, aliquots were taken to determine eluted phage titers. Random clones from these platings were then amplified to determine insert frequency and DNA sequence at each round of panning. Llama VHH sequences were determined from the initial library and after each round of panning from random clones.

8.1.3. PHAGE DISPLAY VECTOR A phage display vector was constructed which created a hybrid fusion protein encoding llama immunoglobulin VHH domains specific for human antigens attached to a truncated version of bacteriophage M 13 coat protein III (Figure 14). The phagemid vector contained a pUC vector backbone, and several M 13 phage derived sequences for expression of gene III fusion proteins and packaging of the phagemid after coinfection with helper phage. The vector was constructed in two forms which differed by the manner in which the fusion between the two protein domains was achieved. The first form included a his6 tag between the two domains as a potential tool for purification and detection of functional fusion proteins. The second form lacked this tag and contained only a single (gly 4 ser) subunit between the two cassettes. Both versions of the vector were constructed with the gene III fusion out of frame and nonfunctional unless a VH, -46was inserted between the leader peptide domain and the gene III domain. All VHH molecules were PCR amplified with SacI-BamHI ends for insertion between the ompA leader peptide (EcoRI-SacI) and the gene III fusion beginning at Spel. Once VHH cassettes with binding activity for human antigens or cells were detected and isolated, the SacI- BamHI fragments could be directly transferred to a mammalian expression vector with compatible sites. The mammalian vector contained a HindIII-SacI leader peptide and a BamHI-XbaI immunoglobulin domain for expressing human, llama, or mouse Ig fusion proteins. This altered vector permitted rapid shuttling of putative antigen binding VHH into a system more amenable to functional analysis.

Individual phage clones were isolated after 3-5 rounds of panning with target i antigens. Eluates from each round of panning were infected into host bacteria and aliquots were plated to LB/amp/tet plates for isolated colonies. Individual clones were inoculated into 2XYT/amp/tet liquid media for several hours, infected with helper phage, and grown under selective conditions overnight at 30°C. Phage supernatants were then prepared by centrifugation to pellet cells and culture supernatants were aliquoted to fresh S* tubes. Precipitated, concentrated phage (100X) were prepared by PEG precipitation of the culture supernatants and resuspension in PBS/I%BSA.

Experimental phage supernatants, precipitates, or helper phage were preblocked 1:1 with 10% nonfat milk/PBS for 30 minutes on ice. Human PBL or monocytes were counted and resuspended in 5% nonfat milk/PBS and preblocked on ice for 30 minutes.

Thereafter, cells were pelleted and resuspended in 5% nonfat milk/PBS, added to i preblocked phage in 25 At per sample, and incubated on ice for 1 hour. Following binding, cells were washed 3 times with alternating 5% milk/PBS and 1% BSA/PBS.

Mouse anti-M13 antibody at 10 Ag/ml in staining media FBS/RPMI 0.1% sodium azide) was added to cells, 100 uzQ per sample, and incubated on ice for 1 hour. Cells were washed 3 times as above. FITC-conjugated goat F(ab')2 anti-mouse Ig (gamma and light, AMI4408 BioSource Int.) 1:100 in staining media was added to cells, 100 p. per sample, and incubated on ice for 30 minutes. Stained samples were then washed and analyzed by flow cytometry.

-47- 8.1.4. SEQUENCING OF DNA FRAGMENTS Subcloned DNA fragments were subjected to cycle sequencing on a PE 2400 thermocycler using a 25 cycle program with a denaturation profile of 96 0 C for seconds, annealing at 50 0 C for 30 seconds, and extension at 72 0 C for 4 minutes. The sequencing primers used were the T7 promoter primer 5'TAA TAC GAC TCA CTA TAG GGA GA3' (SEQ ID NO: 53) and the M13 reverse sequencing primer AGC TAT GAC CAT G3' (SEQ ID NO: 54) (Genosys Biotechnologies, The Woodlands, Texas). Reactions were performed using the Big Dye Terminator Ready Sequencing Mix (PE-Applied Biosystems, Foster City, CA) according to manufacturer's instructions. Samples were ethanol precipitated, denatured, and analyzed by capillary electrophoresis on an ABI 310 Genetic Analyzer (PE-Applied Biosystems). Sequence was edited and translated using Sequencher 3.0 (Genecodes).

8.2. RESULTS Llamas were immunized with human lymphocytes or fusion proteins for the generation of antibody responses against lymphocyte surface antigens as described in Section 7.1.1, supra. After immunization, llama PBL were prepared and VH,-containing DNA fragments were obtained by RT/PCR for the construction of VHH libraries.

A phage display vector was constructed for the cloning of cell-binding

VHH

sequences from llamas immunized with human lymphocytes (Figure 14 and Section infra). Table I shows several isolated phage clones, each of which exhibited a characteristic pattern of binding to different human cell types. Subsequent sequence analysis verified that each clone encoded a unique VHH. In addition, two VHn clones, LI 0 and LI 1, were isolated which reacted with a high molecular weight glycoprotein of 150- 200K Da antigen expressed on CHO cells (Figure 15). Binding of these clones to the target antigen was completely abrogated when CHO cells were pre-treated with trypsin.

VH binding was only partially reduced following treatment of cells with neuraminidase or other endoglycosidases. Thus, the VHH clones reacted with a glycoprotein expressed on the surface of CHO cells.

A number of llama VHH DNA clones were isolated, sequenced and translated. As the phage clones were selected by several rounds of panning on dishes containing an -48- 4** Table I Binding Patterns of Phage Clones of to Different Cell Types antigen or antigen-expressing cells, sequence diversity of the clones was reduced after five rounds of panning. The resulting protein sequences of the VHH were aligned to identify sequence motifs present in this family of antibody variable regions from L.

llama. Sequence alignment revealed two subclasses of VHH sequences in L. llama, which are referred to herein as hybrid (SEQ ID NOS:1-9) and complete (SEQ ID NOS:10-15) VHH sequences. Neither subclass contains a CHI domain of conventional heavy chains, and thus both are expressed as VHH domains fused directly to the hinge-CH2-CH3 domains of an antibody. The hypervariable domains CDRI, CDR2 and CDR3 present in most antibody variable regions are seen in both types of VHH molecule (Figure 16A and 16B). The CDR3 sequence in L. llama VH, domains is longer on average than most CDR3 domains of conventional antibodies composed of heavy and light chains, with the Slongest CDR3 shown in Figure 16B containing 26 amino acid residues. It was previously reported that the CDR3 and CDR2 (or occasionally the CDRI domain) domains in camels usually contained a cysteine residue which was hypothesized to be involved in the formation of a disulfide linkage between the two CDR domains (Muyldermans et al., 1994, Prot. Engin. 7:1129-1135). While this residue is present in the CDRs of the molecules classified as complete VHH (Figure 16B), the sequences of the hybrid subclass do not contain a cysteine in the CDRI, CDR2, or CDR3 domain (Figure S. 16A). Therefore, this class of VH, molecules from L. llama are unique and distinct fromn dromedary species. CDRs derived from this subclass may be superior in stability as they "function independently without disulfide linkages between them.

Based on the aforementioned sequence information, several amino acid residues in the variable regions were identified as important in formation of the VL-VH interface, including residues 11,37, 44, 45, and 47 (Table II). Amino acid residues in four positions were reported to be hydrophilic residues in camel antibodies. Changes in these residues are also found in llama VHH domain, and they may alter the solubility of the unpaired polypeptides. However, although the leucine at residue 11 is usually substituted with a serine in camels, the majority of L. llama sequences contain a leucine at this position. Subsequent clones showed that llama sequences occasionally contained lysine, serine, valine, threonine or glutamic acid at this position.

The amino acids at positions 44, 45, and 47 of camel antibodies have been reported to contain hydrophilic amino acid substitutions for the usual hydrophobic residues observed in conventional VH domains (44-Gly, 45-Leu, and 47-Trp, respectively). There are some exceptions to this general observation of hydrophilic substitution in the hybrid subclass of VHH domains. Residue 45 for all camel and llama species is the only position which contains an invariant hydrophilic Arg residue substituted for the Leu residue found in conventional VH domains. Certain rare sequences containing isoleucine at this position have been observed. Residue 47 (Trp) is more variable, encoding a Gly or Arg in the L. llama complete VHH sequences, but encoding the hydrophobic residues Leu or Phe in the hybrid VH sequences. Subsequent clones have been found to contain tryptophan, isoleucine, serine or alanine as well.

Residue 44 (Gly) is also more variable, substituting Glu or Asp for Gly in the complete VHH subclass, while Glu, Lys, and Gin occur at this position in the hybrid group. A clone containing threonine at position 44 has also been isolated.

In summary, the hybrid subclass family of VHH sequences r >ssess the following characteristics: 1. These variable region polypeptides are derived from antibodies devoid of light chains, which contain no CHI domains.

o 2. They do not contain a disulfide linkage between the CDRs.

3. The amino acid residue at position 11 is usually a leucine instead ofserine.

0* -51 Table Il. Unique Amino Acid Residues in Llama Antibody Variable Regions amino acid 11 37 44 45 47 position Mouse L V G Q C L. V G L W Previously S Y E R F Reported Camel S F E R G Previously S F E R G Reported Llama L F E R G New VHH Llama S F E R G oclones S F D R G K F E R G L F E R G L F E R F L F E R S L F E R A L F D R G L F D R F L F K R F F K R P F Q R L L Y E R L L Y T R L L Y Q R L *L Y A R F L Y E R I L Y E R G L E R G L V E R G L Y K R R L V G L W L V E L W L V E I W L I E R R L I D R R L I D R L L I E I G L A P L W S I E R F S Y Q R W S Y Q R F V F E R F T F E R Y E Y L R M -52- 9. EXAMPLE: CLONING OF LLAMA IMMUNOGLOBULIN

CONSTANT

REGION CODING SEQUENCES 9.1. LLAMA SERUM ASSAY To test the serum reactivity against antigens expressed as llama IgG fusion proteins, the antigen-llamalgG fusion proteins were coupled to "DYNAL" beads and incubated with a serum sample from an immunized llama. The antigen-bead complex was then spun out of solution, washed and incubated on ice in 0.1M citric acid pH 2.3 to remove any antigen-reactive proteins bound during the serum incubation. The antigenbead complex was again spun out of solution and the supematant was neutralized in one half volume 0.1M Tris pH 9.5. An equal volume of SDS-PAGE sample buffer containing 2 -mercaptoethanol as a reducing agent was added to the neutralized proteins and heated at 100°C for 5 minutes. The sample was then run on a 10% Tris-glycine polyacrylamide gel and transferred to a nitrocellulose filter. The filter was blocked in PBS 5% non-fat dry milk 0.01% NP 40, then incubated in blocking buffer 1:5000 dilution goat anti-camelid IgG-HRP conjugate. The filter was then washed in PBS 0.01% NP 40 and incubated in ECL reagent. Proteins were visualized by autoradiography.

9.2. RESULTS Llama constant region coding sequences were cloned using a series of oligonucleotide primers. RNA from llama PBL was isolated and cDNA prepared using random primers or oligo dT. Specific primers designed to amplify the constant domains of the antibody heavy chain were then used to PCR the different llama isotypes.

Alignment of the cloned constant region sequences obtained from llama heavy chain genes is shown in Figure 17. Only sequences from the hinge region to the CH3 domain were compared, since IgG 2 and IgG 3 lack CH1 domain. The hinge domains vary most in length and sequence. Other sequence variation is limited to a few residues scattered throughout the molecule.

Llama constant region coding sequences were ligated with various human leukocyte antigen coding sequences for the expression of fusion proteins. Table III shows a number of recombinant fusion proteins between llama constant regions and human lymphocyte surface antigens which retained the surface antigen binding activities.

-53 The different hinge regions of llama IgG,, IgG, and IgG 3 allow for the design of different types of fusion proteins, depending on whether the naturally-occurring molecule is a monomer or dimer. Fusion proteins with llama constant regions are particularly useful as immunogens for immunizing llamas because they do not stimulate anti-constant region immune responses, thereby maximizing the antibody response against the nonimmunoglobulin portion of the molecule.

In one experiment, a llama was immunized with a human CD40/llama IgG, fusion protein at 250 gg in PBS. Pre-immune serum was collected prior to immunization. Serum was also collected from the llama two weeks after the first immunization, followed by a second immunization. Then serum was again collected two weeks later. When the llama serum collected at different time points was analysed by SDS-PAGE, an anti-CD40 IgG, response was observed following the first immunization.

After the second immunization, anti-CD40 activity was detected in both IgG, and IgG 2 fractions. Thus, the CD40/Ig fusion protein was a potent immunogen in llama; and could be used as a tool for detecting serum reactivity of the host during the course of immunization.

10. EXAMPLE: LLAMALIZATION OF MOUSE ANTIBODY VARIABLE

REGIONS

10.1. MATERIALS AND METHODS 10.1.1. OLIGONUCLEOTIDES FOR LLAMALIZATION A pair of complementary oligonucleotides was designed at the approximate midpoint of an antibody variable region coding sequence. The DNA duplex formed by these annealed oligonucleotides was the starting point for constructing the rest of a Vregion using overlapping single stranded primers which extended the length of the starting oligonucleotides by 18-24 bases at both ends. Since the DNA was very short at 54a a a a. a a a a a a a TABLE III Recombinant Fusion Proteins Between Lla ma Ig Constant Regions and Human Leukocyte Antigens Fusion Protein Constant Regin Expression Prfe yPoenA Atvt huma n nh)C2 tlan(L)ginge Positive by SDS-GE Ye Postive indn to humTa (CD12) lL)IgGI (hinge, Positive by SDS-PAGE Yes Positive for binding to h u C D 4a hn1 )C 2 P s t v b y S S A E Y eP o i v e fo r b n d in g to CH3) 6 cells huCDS64(C 12 L IIgG2I (hinge, CH2, Positive by SDS-PAGE Ye Poiiefrbnigt C8"D6 el huB7-3 L IIgG2 (hinge, CH2, Positive by SDS-PAGE ?9 C H 3) huCD2 L1IIgG, IgG3 Negative when fused to L IIgG2, others pending? 12 this stage, cycling times during the PCR were kept very short (10 seconds annealing and seconds extension times for the first six reactions, and increasing to 30 second extension for the remaining reaction sets) and the molar amount of overlapping primer was kept low as well. Stock solutions of each primer pair were prepared with concentrations ranging from 1 AM to 32 gM. These stocks were then diluted 1:20 into the PCR mix and added to the existing reactions for each successive 10 cycle step. With each consecutive amplification step, the molar concentration of newly added primer was increased and the cycling times were adjusted for slightly longer extensions. In this way, the de novo construction of the desired coding sequence proceeded bidirectionally and was terminated by a final PCR that added unique restriction sites to each end of the DNA to facilitate cloning.

Applying this method to mouse antibody 9.3, the 9 3 V, molecule was resynthesized by diluting all primers in TE at a final concentration of 64 Primer sets were then prepared by mixing the complementary primer pair together in equimolar amounts as the starting pair. All other primers were combined in pairwise sets that overlapped the previous set in both the 5' and 3' direction. These primer pairs were then diluted so that the final concentration of primers ranged from 1 AuM to 32 UM in TE. The reaction for the first PCR cycling was prepared as follows: 12 ng primer pair H31-47 (SEQ ID NO:28) and HAS47-31 (SEQ ID NO:31) were added to the reaction mix so that the final concentration was 0.6 ng/pl, followed by the addition of I Al ofa 1 UM stock of primer pair 2 containing primers H22-36 (SEQ ID NO:27) and H54-40 (SEQ ID NO:34) (final concentration was 50nM), and 17 .l PCR mixture containing ExTaq (TaKaRa Biomedicals, Siga, Japan) dilution buffer, dNTPs, distilled water and ExTaq DNA polymerase (1 unit) according to manufacturer's instructions. The reaction was incubated for 10 cycles with a denaturation at 94 0 C for 30 seconds, annealing at 55 0 C for seconds, and extension at 72 0 C for 20 seconds. Alternatively, for llamalization of the VH, the first primer pair used was (LVI and LI HAS) (SEQ ID NOS:29 and 32) or (LV2 and L2HAS) (SEQ ID NOS:30 and 33) and 1 l of a 1 pM stock of primer pair H22-36 (SEQ ID NO:27) and L1H54-40 (SEQ ID NO:35) (or L2H54-40; SEQ ID NO:36) was added to the first reaction. The second 10 cycle reaction proceeded under the same cycling conditions after addition of 19 pl PCR mix and 1 .l of primer pair H22-36 (SEQ -56- ID NO:27) and H62-49 (SEQ ID NO:37) (2puM stock). A third 10 cycle PCR was performed after addition of 19 pl PCR mix and 1 /l of primer pair H13-27 (SEQ ID NO:26) and H70-57 (SEQ ID NO:38) (4 pM stock). A fourth round of PCR was performed using the same conditions and 1 l1 of primer pair H4-18 (SEQ ID NO:25) and H78-65 (SEQ ID NO:39) (8 zM stock). The fifth round of PCR utilized identical conditions after addition of 19 pl PCR mix and 1 pl of primer pair HRS1-10 (SEQ ID NO: 24) and H84-73 (SEQ ID NO:40) (16pM stock). A 20 cycle reaction was performed under identical conditions after addition of 1 ol primer pair HRS 1-10 and H92-81 (SEQ ID NO:41) (32/pM stock). Eight microliters of the PCR were subjected to agarose gel electrophoresis to check for amplification. The rest of the PCR was purified using PCR quick columns (QIAGEN) according to manufacturer's instructions and eluted in 50 ~1

TE.

New PCR were then set up beginning the whole series of reaction sets over in terms of increasing concentrations of primers and extension time. To 18 l PCR mix was added 1 l PCR product eluate and 1 ul primer pair HRSl-10 and H100-87 (SEQ ID NO:42) (1 MM). Reactions were denatured for 1 minute at 94 0 C, followed by a new cycle program using a 30 second denaturation step at 94C, a 55 0 C annealing step for seconds, and a 72 0 C extension step for 25 seconds. The next PCR was performed under identical conditions, but using 19 pl PCR mix plus 1 /ul primer pair HRS 1-10 and H 104- (SEQ ID NO:43) (21M). The third round of PCR was performed using a 10 cycle program identical to the others except for an increase in the extension time at 72 0 C to seconds, addition of 19 Ml PCR mix and 1 I1 primer pair HRSI-10 and H 11-100 (SEQ ID NO:44) The fourth round of PCR was performed after addition of 19 Ml PCR mix and 1 pl primer pair HRSI-10 and H3RS-104 (SEQ ID NO:46) (8MM). For llamalization, the primer pair used was HRSI-10 and 93VH3'-BAM (SEQ ID NO:45) (8 MM). The 80 pl PCR reaction was PCR-Quick purified and eluted in 30 p/ TE. A final PCR reaction was set up using 0.5 p1 of PCR eluate, 5 ,l 10X ExTaq buffer, 4 pl 2.5 pM dNTPs, 40 Ml dH20, 1 ml primer pair HRS 1-10 and H3RS-104 (or 93VH3-BAM). The reaction conditions included a denaturation step at 94 0 C for 60 seconds, a 30 cycle program with denaturation at 94C for 30 seconds, annealing at 55 0 C for 10 seconds, and extension at 72 0 C for 40 seconds, followed by a final extension at 72 0 C for 2 minutes, -57 and a hold at 4 0 C until recovery. The leader peptide was ultimately attached by repeating two PCR cycles using the subcloned PCR product above as template. The primer pair OKT3/9.3HYB (SEQ ID NO:23) and 93VH3-BAM (or H3RS-104) were included in the first 10 cycle reaction with an extension time of 30 seconds at 72 0 C. A second 10 cycle PCR was performed by adding the primer pair OKT3VHLP-S (SEQ ID NO:22) and 93VH3-BAM (or H3RS-104) under similar reaction conditions as those described for the initial PCRs, but with the longer extension time. Finally, a 30 cycle PCR was performed on the PCR-quick purified product as template and the last primer pair OKT3VHLP-S and 93VH3-BAM (or H3RS-104) as primers to generate a new V, with the leader :peptide from OKT3 V, attached.

10.1.2. LLAMALIZED ANTIBODY PRODUCTION AND FACS

ANALYSIS

Llamalized 9.3 VH molecules LVI and LV2 were constructed as described for rederivation of the 9.3 V using the oligo pairs with alterations in the sequence at residues 37, 44, 45, and 47 in the mature VH (Figure 18). These PCR products were digested with HindIII and BamHI and subcloned into the pXD expression vector. The vector also contained a BamHI-XbaI fusion protein cassette encoding the llama IgG, constant region. Similar constructs were also made using the llama IgG, and IgG 3 constant domains. The fusion protein expression cassette was then transiently transfected into COS cells in serum free medium and the supernatants were harvested 48 hours later. Culture supematants were concentrated ten fold using AMICON filtration units, and 100 pc incubated with 106 Jurkat T cells for 2 hours on ice. Cells were spun at 1300 rpm for 5 minutes, supernatants aspirated, and resuspended in 100 *l staining buffer (PBS, 2% FBS) containing 1:40 FITC anti-llama (Kent Labs) or FITC-anti mouse reagent (Biosource International) for 1 hour on ice. Cells were spun again at 1300 rpm for 5 minutes, supematants aspirated, and washed in 200 y1 staining buffer. Final cell pellets were resuspended in 400 p, staining buffer and analyzed with a FACSCAN cell sorter.

10.2 RESULTS Based on the observed characteristics of llama VHH domain, a method was developed to convert non-llama antibody heavy chains to ones that would not require -58pairing with a light chain in a process herein referred to as llamalization. V H sequences from isolated mAbs were determined or identified using sequence data available from the Genbank DNA sequence database. These sequences were used to design short, overlapping oligonucleotides encoding short peptides of the V, domain. An accompanying PCR cycling method was developed which permitted de novo synthesis of the VH domain using the appropriate combinations of these oligonucleotides. Sequence changes were incorporated into the oligonucleotides which spanned the residues identified as important in llama VHH structural stability-11, 37, 44, 45, and 47 (Table II). In that regard, position 11 of any antibody may be changed to S, K, V, T or E; position 37 may be changed to Y, F, L, V, A or I; position 44 may be changed to E, D, K, S" T, Q, P, A or L; position 45 may be changed to R, L or I; and position 47 may be .changed to F, G S, A, L, I, R, Y, M or W.

The llamalized VH domains were subcloned as HindIII+XbaI fragments into pUC 19 for sequence analysis. Once the sequence changes were verified, the cassettes were shuttled into a mammalian expression vector encoding a leader peptide and an Ig fusion domain for expression studies. Culture supernatants from transient transfection experiments were then screened for expression of soluble Ig fusion protein and antigen binding capacity.

The aforementioned method was applied to an anti-CD28 antibody 9.3 using the overlapping oligonucleotides shown in Figure 18. A pair of complementary oligonucleotides were designed at the approximate midpoint of the antibody V-region coding sequence. The DNA duplex formed by these annealed oligonucleotides was the starting point for constructing the rest of the V-region using overlapping single stranded primers which extended the length of the starting oligonucleotides by 24 bases at both ends. Since the DNA was very short at this stage, cycling times during the PCR were kept very short and the molar amount of overlapping primer was kept low as well. With each consecutive amplification step, the molar concentration of newly added primer was increased and the cycling times were adjusted for slightly longer extensions. In this way, the de novo construction of the desired DNA sequence proceeded bidirectionally and was terminated by a final PCR that added unique restriction sites to each end of the DNA to facilitate cloning.

-59- Figure 19 shows a histogram display for Jurkat cells stained with llamalized version 2 of 9.3 antibody culture supematant (1Ox) as compared with second step FITCconjugated anti-llama antibody alone. The results demonstrate that a llamalized mouse anti-CD28 antibody was able to bind to its target antigen on cells as a heavy chain-only antibody.

11. EXAMPLE: CDR PEPTIDES DERIVED FROM ANTI-CD3 ANDANTI- CD28 ANTIBODIES BOUND TARGET ANTIGENS This section describes the generation of soluble recombinant fusion proteins containing the extracellular domains of CD36, E or y subunit. Co-expression of CD3E with either CD3y or CD36 results in fusion proteins that interacted at high affinities with a number of anti-CD3 mAbs including the ones that bound only to native conformational epitopes. Thus, this represents a method for producing native CD3e/6 or CD3e/y heterodimers. This system is suitable for defining the conditions required for CD3 heterodimer formation, providing the tools to identify potential ligands for CD3 heterodimers, screening for molecules potentially capable of interfering with the interaction between the CD3 complex and the TCR on T cells.

11.1. MATERIALS AND METHODS 11.1.1. PEPTIDE SYNTHESIS Peptides corresponding to the entire CDR3 regions of anti-CD3 and anti-CD298 mAbs were synthesized, and Tyr/Phe-Cysteine residues were added to both amino and carboxyl termini. Modifications ofpeptides were made by eliminating one amino acid of the CDR3 region at a time from the terminus. Peptide synthesis was carried out on solid phase by using Fmoc chemistry (HBTU/DIEA activation and TFA cleavage). Crude peptides were combined in a batch of 3-5 peptides and cyclized by air oxidation at pH Crude cyclic peptides were purified on a reverse phase HPLC, lyophilized and characterized by analytical HPLC and mass spectroscopy.

11.1.2. BIACORE BIACORE uses surface plasmon resonance (SPR) which occurs when surface plasmon waves are excited at a metal/liquid interface. Light is directed at, and reflected due to bimolecular interactions between analyte (in solution) and ligand (immobilized).

CD3E6huIg, CD3EEhulg and CD28huIg were covalently immobilized on a carboxymethy dextran chip using EDC/NHS chemistry followed by blocking with ethanol amine. Peptides were dissolved in HBS buffer at pH 7.2 with or without 1% DMSO, and were allowed to pass over these fusion protein-immobilized surfaces. Nonspecific binding was substrated by passing these peptides over a controlled surface prepared by immobilizing EDC/NHS alone followed by ethanolamine.

11.1.3. CONSTRUCTION OF CD3 DIMERS To generate a CD3E-Ig fusion construct (phCD3E-Ig), a cDNA encoding the extracellular domain of CD3e including the native start codon and the leader sequence was amplified from total RNA ofanti-CD3 plus anti-CD28-activated T cells (72 hours) by RT-PCR using the following primers set: Forward primer, 5' GCG [CTC GAG] CCC ACC ATG CAG TCG GGC ACT CAC TGG (SEQ ID NO:55) and reverse primer GGC C[GG ATC C]GG ATC CAT CTC CAT GCA GTT CTC ACA (SEQ ID NO:56).

Nucleotides in parenthesis are the XhoI (CTC GAG) and BamHI (GGA TCC) sites .designed for cloning. PCR products were digested with Xhol and BamHI. The cut fragment was purified. A CDM8 expression vector harboring a genomic fragment encoding human IgG, hinge-CH2-CH3 was cut with Xhol and BamHI. Ligation of the cut vector and PCR product placed the cDNA encoding CD3E extracellular domain in front of and in-frame with the genomic fragment encoding IgG, hinge-CH2-CH3. The CMV promoter in this vector controlled expression of CD3-Ig fusion protein in mammalian cells.

A cDNA fragment encoding human IgG, hinge-CH2-CH3 was used as a fusion partner for the CD36-(phCD3801g) and CD3y-Ig (phCD3y-Ig) constructs instead of a genomic fragment. This fragment was cloned into the BamHI and XbaI sites of the pDl 8 expression vector, also containing a CMV promoter for protein expression. Fragments of cDNA encoding the extracellular domains of CD35 and CD3y including the native start codons and leader sequences were isolated by RT-PCR from the same total RNA described above. The primers used are as follows: -61 CD36 forward, 5' GCG ATA [AAG CTT] GCC ACC ATG GAA CAT AGC ACG TTT CTC (SEQ ID NO:57), CD38 reverse, 5' GCG [GGA TCC] ATC CAG CTC CAC ACA GCT CTG (SEQ ID NO:58), CD3y forward 5' GCG ATA [AAG CTT] GCC ACC ATG GAA CAG GGG AAG GGC CTG (SEQ ID NO:59) CD3y reverse, 5' GCG [GGA TCC] ATT TAG TTC AAT GCA GTT CTG AGA C (SEQ ID Nucleotides in parenthesis are the HindIII (AAG CTT) and BamHI (GAA TTC) sites for cloning. PCR products were cut with HindIII and BamHI. Purified cut PCR fragments were then cloned into HindIII and BamHI cut hinge-CH2-CH3 containing pD 18 vector.

The cDNA encoding CD36 and CD3y extracellular domains was placed in front of and •in-frame with that encoding IgG, hinge-CH2-CD3.

Because of the presence of two cysteine residues in the hinge region of the IgG, hinge- CH2-CH3 fragment that could form disulfide linkages, fusion proteins were o• usually expressed as dimers.

Transient expression in COS-7 cells was used to generate different CD3-Ig fusion proteins. The plasmids phCD3e-Ig, and phCD3y-Ig were transfected individually or in combinations of phCD3E-Ig phCD36-Ig and phCD3E-Ig phCD3y-Ig into COS-7 by the DEAE-dextran method. Transfected cells were maintained in medium supplemented with a low concentration, FBS and insulin. Spent media were collected in threeday intervals up to three weeks post transfection. Fusion proteins were then purified from spent media by protein A-Sepharose chromatography. Fusion protein expression was confirmed by SDS-PAGE and ELISA using anti-CD3 mAb.

11.2. RESULTS CD3-Ig fusion proteins were characterized by ELISA using a number of anti-CD3 mAbs including G19-4, OKT3, BC3, and 64.1 Anti-CD3 mAbs were immobilized to capture CD3-Ig. An antibody-horseradish peroxidase conjugate specific against human IgG hinge-CD2-CD3 was used to detect the binding of CD3-Ig to anti-CD3 mAbs. Like the control CD4-Ig, no binding of CD36-Ig to G19-4 was detectable even at 100 g/ml of -62the fusion protein (Figure 20). Although binding of CD3E-Ig and CD3y-Ig to G19-4 was detectable, it did not reach saturation even at concentrations as high as 100 ulg/ml. On the other hand the CD3E6-Ig and CD3Ey-Ig heterodimers bound to G 19-4 at much higher affinities (Figure 20). CD3e6-Ig and CD3ey-Ig saturated at 4 pg/ml and pg/ml in this assay, respectively. Similarly, OKT3, BC3, and 64.1 anti-CD3 mAbs also showed much better binding to the CD3E8-Ig heterodimer than the CD3ey-Ig. These data indicate that co-expression of either CD3e-Ig with CD36-Ig, or to some extent CD3E-Ig with CD3y-Ig, in COS cells resulted in heterodimeric CD3-Ig fusion proteins that were folded to their native conformation as defined by anti-CD3 mAbs. In addition, binding affinities of the CD3-Ig fusion proteins to different anti-CD3 antibodies were measured by BIACORE, and the results are shown in Table IV. Thus, CD3e6 and CD3Ey heterodimers may be used in detecting anti-CD3 antibody activity in antibodycoated plates or beads, as well as in screening of small molecules or peptides that bind specifically to CD3.

.o Table IV. Binding Affinities of Anti-CD3 Antibodies to CD3-Ig Fusion Proteins As Measured By BIACORE f o *oo o Anti-CD3 Antibody Affinity (nM) CD368-Ig CD3EE-Ig G19.4 1.28 uM* OKT-3 10.6 9M* BC-3 5.7 gM* 64.1 7.58 gM* MOPC (control) Not detectable Not detectable uM* Binding was at micromolar level or below.

The CDR3 region of an anti-CD3 mAb and an anti-CD28 mAb was determined, and peptides corresponding to this region were synthesized. Cysteine residues were added to the ends of the peptides, followed by an aromatic residue tyrosine or tryptophan (Greene, W095/34312). Upon air oxidation, the peptides were cyclized due to the formation of a disulphide linkage between the cysteines. As a result, the aromatic residues were in the exocyclic portion of the cyclized CDR peptides.

63 The binding affinities of the various peptides to their target antigens in the form of Ig fusion proteins were measured by BIACORE. Table V shows that a number of peptides exhibited high binding affinities for CD3e8-Ig, whereas several peptides exhibited binding affinities for CD28-Ig. Thus, small CDR peptides may be used in lymphocyte activation in place of antibodies.

Table V. Binding Affinities of Peptides Derived From CDR3 Regions Of Two m.Abs @0 0S 0* 0 0* 0~ 0* 0*0 *0 a 0* *0 0 *000 *0 *0 0 0* Peptide* Binding Affinity CD3E6Ig** CD28Ig YCRSAYYDYDGIAYCW (SEQ ID NO:61) 7pM l66pM YCSAYYDYDGIAYCW (SEQ ID NO:62) YCAYYDYDGIAYCW (SEQ ID YCRYYDDI-YSLDYCW (SEQ ID NO:64) nd nd YCYYDDHYSLDYCW (SEQ ID YCYDDI-YSLDYCW (SEQ ID NO:66) YCDDHYSLDYCW (SEQ ID NO:67) YCDHYSLDYCW (SEQ ID NO:68) YCARDSDWYFDVCW (SEQ ID NO:69) 5OpM nd YCARSDWYFDVCW (SEQ ID YCARDWYFDVGW (SEQ ID NO:71) YCGYSYYYSMDYCW (SEQ ID NO:72) nd L OA~M YCYSYYYSMDYCW (SEQ ID NO:73) YCSYYYSMDYCW (SEQ ID NO:74) YCYDYDGCy (SEQ ID NO:75) l104M nd YCYDYDYCY (SEQ ID NO:76) nd n YCYDYDFCY (SEQ ID NO:77) nd nd YCYDDHTCY (SEQ ID NO:78) nd nd YCYDDHQcy (SEQ ID NO:79) nd nd YCFDWKNCY (SEQ ID NO:80) O.5pM nd Peptides were made individually, pooled ina batch of 3-5 peptides, cyclized, purified and characterized as poois.

=CD3 Ebhulg used for the binding affinity was impure and was a mixture of several components which were not fully characterized.

nd non detectable binding 64 The present invention is not to be limited in scope by the exemplified embodiments which are intended as illustrations of single aspects of the invention and any sequences which are functionally equivalent are within the scope of the invention.

Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and accompanying drawings. Such modifications are intended to fall within the scope of the appended claims.

All publications cited herein are incorporated by reference in their entirety.

Throughout this specification and the claims which follow, unless the context o" requires otherwise, the word "comprise", and variations such as "comprises" and "comprising", will be understood to imply the inclusion of a stated integer or step or group @o of integers or steps but not the exclusion of any other integer or step or group of integers or steps.

The reference to any prior art in this specification is not, and should not be taken as, an acknowledgment or any form of suggestion that that prior art forms part of the common general knowledge in Australia.

S05 ooo• •o o

*Q

00 S S S 0 0 65 EDITORIAL NOTE APPLICATION NUMBER The following Sequence Listing pages6tooare part of the description. The claims pages follow on pages g q SEQUENCE LISTING <110> Ledbetter, Jeffrey Hayden Ledbetter, Martha Brady, Bill Grosmaire, Laura Law, Che-Leung Dua, Raj <120> COMPOSITIONS AND METHODS FOR REGULATING LYMPHOCYTE

ACTIVATION

<130> <160> <170> 9113 -0019-999 FastSEQ for Windows Version Ile 1 Ser Gly Ala Gly 65 Gln Ala Gin Pro Lys 145 Pro Thr Asn Gly Ser 225 <210> 1 <211> 2 <212> P: <213> L.

<400> 1~ Arg Leu L Leu. Arg L Met Gly Th 35 Gly Ile SE 50 Arg Phe T1 Met Asn Se Asp Lys Ax Val Thr Va.

115 Gin Pro GI 130 Cys Pro Al Pro Lys Pr Cys Val Va 18 Gly Thr Le 195 Gly Ser Le 210 au 0 1i Val 5 Ser Tyr Ser Ile Leu 85 Gly Ser Pro Pro Lys 165 Val Met Glu Ser Gly Gly Gly Leu Ala Gin Pro Gly Gly

RT

lama llama Cys Arg Thr Ser 70 Lys Pro Ser Gin Glu 150 Asp Asp Al a Ala Gin Asn 55 Arg Pro Val Glu Pro 135 Leu Val Val Arg Ala Ala 40 Ile Asp Gl u Ile Pro 120 Asn Leu Leu Gly Gly Ser 25 Pro Pro Asn Asp Thr 105 Lys Pro Gly Ser Gln 1.85 VTal Gly Gly Ass Ala Thr 90 Val1 Thr Thr Gly Ile 170 Glu Trp *Val Lys Tyr Lys 75 Ala Tyr Pro Thr Pro 155 Ser Asp Arg Gin.

Ser Asn Val Trp Lys Glu 140 Ser Gly.

Pro Gly) Leu 220 GIl Pro Lys Thr Tyr Gly Pro 125 Ser Val A.rg Glu Leu Gly 30 Glu Ser Val Tyr Lys 110 Gln Lys Phe Pro Val 190 Val 15u Leu Val Tyr Cys Gly Pro Cys Ile Glu 175 Ser Gln Asp Val1 Lys Leu Asn Thr Gin Pro Phe 160 Val Phe Pro 200 ii Thr Leu Ser 215 Val Asn Leu Asp Leu Arg Leu Tyr 66 <210> 2 <211> 183 <212> PRT Ile Ser Thr Ala Arg Met Ser Phe Gin Pro 145 Lys <213> L.

<400> 2 Arg Leu LE Leu Arg Lf Leu Gly Ti Asp Ile Se Phe Thr 11 Asn Leu Le Glu Asp Ar Pro Ala Ar 115 Val Ala Va 130 Gin Pro G1 Cys Pro Al lama llama a) g 0 n a Val 5 Ser Phe Gly Ser Lys Arg Lys Ser Pro Pro 165 Glu Ser Gly Gly Gly Leu Val Arg Ala Gly Gly 3.0 *.0 0 0* 0 0. 0.

Cys Arg Ser Arg 70 Phe Thr Phe Ser Gin 150 Glu Ala Gin Ile 55 Asp Al a Giu Met Glu 135 Pro Leu Al a Ala 40 Thr Asn Asp Leu Gin 120 Pro Asn Ser 25 Pro Phe Al a Thr Lys 105 Tyr Lys Pro 10y Gly Tyr Gin Al a 90 Lys Glu Thr Thr Arg Lys Al a Asn 75 Val1 Glu Tyr Pro Thr Ile Glu Asp Thr Tyr Arg Trp Lys 140 Glu Phe Pro Ser Val1 Tyr Ala Gly 125 Pro Ser Ser Glu Val Tyr Cys Asn 110 Gin Gin Lys 1s Asn Tyr Phe Val Lys Gly Leu Gin Ala Ala Ser Trp Gly Thr Pro Gin Cys Pro iss Leu Gly Gly Pro Ser Val Leu Ser Ser 170 7q Pro Pro Lys Pro Lys Asp Val 180 Ile Ser Thr Ala Gly Gin Ala Gly Pro Cys <210> 3 <211> 204 <212> PRT <213> Lla.

<400> 3 Arg Leu Leu Leu Arg Leu Met Gly Trp, Glu Ile Thr Arg Phe Thr Met Asn Ser Asp Ile 1l-1e 100 Thr Gin Val 115 Gin Pro Gin 130 Pro Lys Cys ma. llama Val Ser Tyr Ala Ile Leu Thr Thr Pro Pro Glu Cys Arg Asp Phe 70 Lys Thr Val1 Gin Ala Ser Val1 Gin Gly 55 Gl y Al a Asp Ser Pro 135 Pro Gly Ala Thr 40 Ser Asp Giu Trp Ser 120 Gin Glu Gly Ser 25 Pro Gin Asn Asp Arg 105 Glu Pro Leu Gly Leu Gly Arg Gly Ile Asn Tyr Asp Lys 75 Thr Ala 90 Ser Ser Pro Lys Asn Pro Leu Gly Val Ile Gin Val Lys Asp Arg Thr Thr 140 Gly Gin Phe Pro Asp Thr Tyr Tyr Pro 125 Thr Pro Al a Thr Giu Ser Val1 Tyr Trp 110 Lys Giu Ser Gly Ile Leu Val Tip, Cys Gly Pro Ser Val Gly Arg Val Lys Leu Ala Gin Gin Lys Phe -67 0 0 0 6.

1

I

G

T

T

1

G

I:

145 Ile Phe Pro P Giu Val Thr C 1.

Ser Phe Asn G 195 <210> 4 <211> 21 <212> P~ <213> L <400> 4 Ile Arg Leu Le 1 Ser Leu Arg Le 6ai Met Gly Tr 35 l.a Ala Ile As .ys Gly Arg Ph ~eu Gin Met Asi Lla Val Arg Th 10( ly Tyr Trp G1~ 115 hr Pro Lys Prc 130 hr Thr Giu Sex 45 ly Pro Ser Val le Ser Gly Arg 180 Lu Asp Pro Giu 195 <210> <211> 206 <212> PRT <213> Liat <400> e Arg Leu Leu Leu Arg Leu a Net Thr Trp, a Val Val Gly Y Arg Phe Thr

I

p n e, n IVal LSex Phe Trp Thr Ser 85 Arg Gin Gin Lys Phe 165 Pro Val Giu Ser Cys Ala Arg Gin Ser Val 55 Ile Ser 70 Leu Lys Gin Arg Giy Thr Pro Gin 135 Cys Pro 150 Ile Phe Glu Val Ser Phe 1 Gi) Al a Aila 40 Gly Arg Pro Leu Gin 120 Pro Lys Pro rhr ~sn ~00 Gly Gly Leu Val 20 Ser Giu Arg Asp 25 Pro Gly Lys Giu Gly Thr Tyr Tyr 60 Asp Asn Ala Lys 75 Giu Asp Thr Ala 90 Asn Ile Arg Ala 105 Val Thr Val. Ser Gin Pro Gin Pro 140 Cys Pro Ala Pro 155 Pro Lys Pro Lys 1 170 Cys Val Val ValA 185 Gly Thr Leu Met Gir Phe Pro Thr Asn Val Asp Ser 125 Gln 31u ISp LSp Ja 1Pri Gi' Gil Asj Thr Tyr Giu 110 Glu Pro Leu Val1 Val 190 Lys 0 Gly Gly r Ser Ser a Phe Vai Ser Val.

*Val Tyr *Ser Cys Asp Tyr Pro Ly~s Asn Pro Leu Gy 160 Leu Ser 175 Gly Gin Pro Asn ISO 155 160 'ro Lys Pro Lys Asp Val Leu Ser Ile Ser Gly Arg Pro 165 170 175 ys Val Val Vai Asp Val Gly Gin Giu Asp Pro GJlu Vai s0 185 190 ly Thr Leu Met Ala Lys Ala Giu Phe 200 Lama llama 2 ma. llIama Se Al.

Al.

Gi' Val 5 Ser Tyr Gly Ile Giu Cys Arg Gly Ser Ser Gly Gly Gly Leu Val Gin Ala Gly Gly 10 Thr Thr Ser Giy Ile LYS Phe Gly Ile Thr 25 Gin Thr Pro Leu Asn Giu Pro Glu Leu Val.

40 Gly Ser Thr Leu Tyr Giu Gly Arg Val Lys 55 Arg Asp Asn Asp Lys Asn Thr Ala Tyr Leu -68- Gl Al.

Try Lys Glu 145 Ser Gly Pro a Met As I Ala Al~ Gly Gir *Pro Gir 130 Ser Lys *Val Phe A~rq Pro Glu Val 195 <210> <211> <212 <213 <400> Arg Leu a Ser Leu 85 Ser Ile 100 Gly Thr Pro Gin Cys Pro Ile Phe 165 Glu Val 180 Ser Phe 70 Lys Leu Gin Pro Lys 150 Pro Thr A.sn Prc Al a Val1 Gin 135 Cys Pro Cys Giy Giu Asp Ala Ser 105 Thr Val 120 Pro Gin Pro Ala Lys Pro Val Val 185 Thr Leu 200 Thr 90 Ser Ser Pro Pro Lys 170 Val Met 75 Aila Al a Leu Gin Glu 155 Asp Asp Ala Val Giu Giu Pro 140 Leu Val Vai Lys *Tyr Tyr Thr Val 110 Pro Lys 125 Asn Pro Leu Gly Leu Ser Gly Gin 190 Pro Asn 205 Cys Gly Gin Tyr Thr Pro Thr Thr Giy Pro 160 Ile Ser 175 Glu Asp 208

PRT

Llama llama 6 Leu Val Glu Ser Gly Gly Gly Leu Val Gin Arg Gly Ala Ile

I

Ser Leu Arg Leu Thr Cys Val Val Ser Gly Ile 20 Ala Met Gly Trp Phe Ala Lys Leu Ala Asp Pro Thr 145 Gly Ile Ser s0 Gly Gin Al a Leu Lys 130 Thr Pro Ser 35 Ile Arg Leu Leu Gly Thr Glu Ser Al a Phe Ala Asn 100 Trp Pro Ser Val Tr-p Thr Asn 85 Gly Trp Lys Lys Phe 165 Arg Asp Val1 70 Leu Ala Gly Pro Cys I50 Ile Gln Gly 55 Ser Gin Trp Gin Gin 135 Pro Phe 25 Ala Pro Gly 40 Asp Glu Thr Arg Asp Val Pro Giu Asp 90 Pro Ser Ser 105 Gly Thr Gin 120 Pro Gin Pro Lys Cys Pro Pro Pro Lys Gin Trp Ala 75 Thr Ile Val Gin Ala Phe Lys Tyr Lys Ala Ala Thr Pro -140 Pro is Vail Pro Gly Asn Thr Thr Val 125 Gln Glu Asp Leu Asp Ser Tyr Met 110 Ser Pro Leu Arg Phe Ser Val1 Ser Thr Leu Asn Leu Trp Val Val Tyr Cys Pro Glu Pro Gly 160 Pro Lys Asp Val Leu Gly Arg Pro Glu Val Thr Cys Val Val Val Asp 180 185 Glu Asp Pro 195 <210> <211> <212> <213> 175 Val Gly Gln 190 Lys Pro Asn lu Val Ser Phe Asn 200 Gly Thr Leu Met Al a 205 204

PRT

Llama llama 69 <400> 7 Ile Arg Leu Leu Val Giu Ser Gly Gly Gly Leu Val Gin Thr Gly Asp Ser Leu Lys Leu Ser Cys Val Ala Ser Gly Arg Asn Phe Ser Ser Tyr His Ala Gly Gin Al a Trp Lys Lys 145 Phe Pro Val Met, Val Arg Met Asp Gly Pro 130 Cys Ile Giu Ser <23 <23 Ala Ser Phe Asn Asp Gin Gin Pro Phe Tr Trp Thr Ser His 100 Gly Pro Lys Phe Lys Leu Leu Val Thr Gin Cys Arg Gly Ser 70 Lys Thr Gin Pro Pro 150 Gin Thr Pro 40 Gly Ser Glu 55 Arg Asp Gly Pro Giu Asp Arg Gly Ala 105 Val Thr Val 120 Gin Pro Gin 135 Ala Pro Glu Asp Lys Tyr Tyr Ala Lys 75 Ser Gly 90 Ser Lys Ser Ser Pro Asn Leu Leu Glu Lys Asn Val Ala Glu Pro 140 Gly Ser Gin Prc Asn Thr Tyr Ser Pro 125 Thr Gly Ile "lu Giu Ser Val Tyr Tyr 110 Lys Thr Pro Ser Asp PhE Val Tyr Cys Arg Thr Glu Ser Gly 1 Pro Val *Lys *Leu Ala Tyr Pro Ser Val 160 Arg Glu Pro Pro Lys Pro Lys Asp Val Leu

J

t al Thr 180 The Asn 195 LO> 8 211 165 170 Cys Val Vai Val Asp Val Gly 185 Gly Thr Leu Met 200 Ala Lys Pro Asn <212> PRT <213> Llama llama Ile

I

Ser Tyr Ala Lys Leu Ala Asp Ser Pro 145 <400> 8 Arg Leu L~ Leu Arg LE Met Gly Ti Leu Ile Se Gly Arg Ph~ Gln Met As Ala Asn Ii Lys Arg Th 115 Ser Giu Pr 130 Asn Pro Th r Val 5 Ser Phe Arg Thr Ser Ala Tyr Lys Thr Giu Ser Gly Gly Gly Leu Val Gin Ala Gly Gly 10 Cys Arg Ser Ile 70 Leu Al a Ser Thr Glu 150 Thr Gin Gly 55 Ser Ile Gly Tyr Pro 135 Ser Aia Ser 25 Ala Pro 40 Gly Ser Arg As p Pro Glu Trp Asp 105 Trp Gly 120 Lys Pro Lys Cys 10y Gly Thr Asn Asp 90 Thr Gin Gin Pro Arg Lys Asp Ala Thr Leu Gly Pro Lys Thr Glu Tyr Lys Ala Ser Thr Gin 140 Cys Phe Pro Ala Asn Asp Arg Gin 125 Pro Pro Ser Glu Asp Thr Tyr Asp 110 Val Gin Al a Arg Ser Ser Pro Tyr Trp Thr Pro Pro Tyr Val Val Tyr Cs Arg Val Gin Giu 155 .LD v Leu LeU Gly Gly Pro Ser Val Phe Ile Phe Pro Pro Lys Pro Lys Asp J~U

~I

170 70 Val Leu Ser Ile Ser Gly Arg Pro Glu Val Thr Cys Val Vai Val Asp 180 185 190 Val Gly Gin Giu Asp Pro Glu Val Ser Phe Asn Gly Thr Leu Met Ala 195 200 205 Lys Pro Asn 210 Ile Ser Ala Ala Lys 65 Leu Al a Tyr Pro Ser 145 Val Arg Giu Ile 1 Ser Tyr Val Val <210> 9 <211> 2( <212> P1 <213> L] <400> 9 Arg Leu LE Leu Arg Le 20 Met Gly Tz 35 Arg Ile Se so Gly Arg Ph~ Gln Met As Ala Asp Se Trp Gly G1 115 Lys Pro G1 130 Lys Cys Pr Phe Ile Ph Pro Giu Va.

18 Val Ser Ph 195 <210> <211> 20~ <212> PR' <213> Li.

<400> Arg Leu Lel Leu Gin Lei Ala Val GI Ser Cys Lei Lys Gly Ar

-P

r e n r 0 e 1 0 e Val Ser Phe Arg Thr Ser Asp Gly Pro Lys Pro 165 Thr Asn Glu Cys Arg Val Ile 70 Met Tyr Thr Gln Arg 150 Pro Cys Gly Ser Gly Gly Gly Leu Val Gin Ala Gly Asp Ala Gin Gly 55 Ser Lys Gly Gin Pro 135 Pro Lys Val Thr Ala Ala 40 S er Arg Ala Pro Val 120 Gin Ala Pro Val Leu 200 Ser 25 Pro Ser Asp Giu Gly 105 Thr Pro Pro Lys Val 185 Met Gly Arg Gly Lys Thr Phe Asn Ala 75 Asp Thr Arg Arg Val Ser Gin Pro Glu Leu 155 Asp Val 170 Asp Val Ala Lys Thr Giu Tyr Lys Al a Ser Ser Asn 140 Leu Leu Gly Pro Phe Pro Thr Asn Val Ser Glu 125 Pro Gly Ser Gln Asn 205 Thr Glu Asp Thr Tyr Giu 110 Pro Thr Giy Ile Glu 190 Asn Phe Ser Met Tyr Tyr Lys Thr Pro Ser 175 Asp Ty-r Val Val Tyr Cys Asp Thr Glu Ser 160 Gly Pro Lama llama 9

T

ama l lama u Val Giu 5 a1 Ser Cys ~r Trp Phe a Ser Arg a Phe Thr Ser Gly Gly Ala Thr Ser 25 Arg Gin Ala 40 Tyr Gly Gly 55 Ser Ser Ser Gly Leu Vai Gin Ala Gly Gly 10 Gly Val Leu Thr Ser Giy Asp Pro Gly Lys Giu Arg Giu Gly Pro Thr Leu Tyr Ala Asp Ser Asp Ala Ala Lys Thr Lys Val 75 -71 Tyr Leu Cys Thr Tyr Asp Lys Thr 130 Pro Thr 145 Gly Giy Ser Ile Gin Giu Ile Gin Ala Tyr 115 Pro Thr Pro Ser Asp 195 Met His 100 Trp Lys Giu Ser Gly 180 Pro Asn Asn Ile Ser Gly Gin Pro Gin Ser Lys 150 Val. Phe 165 Arg Pro Glu Val Leu Cys Gly Pro 135 Cys Ile Giu Ser Lys Asp Thr 120 Gin Pro Phe Val Phe 200 Pro Glu Asp 90 Trp Asn Ile 105 Gin Val Thr Pro Gin Pro Lys Cys Pro 155 Pro Pro Lys 170 Thr Cys Val 185 Asn Gly Thr Thr Ile Val1 Gin 140 Al a Pro Val1 Leu *Ala Asn Ser 125 Pro Pro Lys Val Met 205 Val Pro 110 Ser Gin Giu Asp Asp 190 Al a Tyr Tyr Asn Giu Glu Pro Pro Asn Leu Leu 160 Val Leu 175 Val Giy Ser Arg 9 .9 9 9* 9* *9 9.

9* 9* .9 <210> 11 <211> 217 <212> PRT <213> Llama 1 <400> 11 Ile Arg Leu Leu Vai 1 5 Ser Leu Arg Leu Ser 20 Tyr Ala Ile Gly Trp Val Ile Cys Met Ser 50 Val Lys Gly Arg Phe Tyr Leu Gin Met Giu 85 Cys Ala Aia Asn Tyr 100 Ala Asp Tyr Cys Ser 115 Gin Gly Thr Gin Vai 130 Gin Pro Gin Pro Gin 145 Pro Lys Cys Pro Ala 165 Phe Pro Pro Lys Pro 180 Val Thr Cys Val Vai 195 Phe Asn Giy Thr Jeu 210 ilama Glu Ser Gly Gly Gly Leu Val Gin Pro Giy Asp Cys Phe Al a Thr 70 Arg Leu Gly Thr Pro 150 Pro Lys Val Met Ala Arg Ser 55 Ile Leu Giy Ser Vai 135 Gin Glu Asp' Asp' Ala 215 Val Gin 40 Asp Ser Lys Arg Gly 120 Ser Pro Leu Val VJai 200 Giu Ser 25 Ala Giy Arg Pro Val 105 Ser Ser Asn Leu Leu 185 Giy Phe 10 Gly Val Phe Thr Leu Asp Asp Pro Gly Lys Giu Arg Glu Gly Ser Thr Asp Asp 75 Glu Asp 90 Arg Gly Vai Val Glu Pro Pro Thr 155 Gly Gly 170 Ser Ile Gin Giu Tyr Asp Thr Ser Tyr Lys 140 Thr Pro Ser Asp Tyr Lys Ala Ala His 125 Thr Glu Ser Gly Pro 205 Ser Asn Thr Ile 110 Phe Pro Ser Val Arg 190 Glu Asp Thr Tyr Arg Trp Lys Lys Phe 175 Pro Val Ser Leu Tyr Al a Gly Pro Cys 160 Ile Glu Ser <210> 12 <211> 219 72 <212> PRT <213> Llama llama <400> 12 Ile Arg Leu Leu Val Giu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Val Phe Thr Arg Asp Tyr 25 Tyr Val Ile Ala Trp, Phe Arg Gin Ala Pro Gly Lys Glu Arg Giu Gly 40 Val Set Cys Ile Ser Thr Arg Gly Ser Thr Tyr Tyr Ala Asp Ser Val 55 Lys Gly Arg Phe Ala Ile Ser Gly Asp Asn Asp Lys Met Thr Val Tyr 70 75 Leu Gin Met Asn Asn Leu Lys Pro Giu Asp Thr Ala Vai Tyr Tyr Cys 90 Gly Ala Leu Ile Asn Trp Tyr Ser Pro Pro Asn Thr Asp Tyr Asp Ser *100 105 110 **Ala Trp Cys Arg Gly Arg Ser Leu Gly Asp Tyr Gly Leu Asp Tyr Trp :8115 120 125 *Gly Lys Gly Thr Leu Val Thr Val Ser Ser Giu Pro Lys Thr Pro Lys *.*130 135 140 Pro Gin Pro Gin Pro Gin Pro Gin Pro Asn Pro Thr Thr Glu Ser Lys *145 150 15.5 160 Cys Pro Lys Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe 165 1.70 175 Ile Phe Pro Pro Lys Pro Lys Asp Vai Leu Ser Ile Ser Gly Arg Pro *.:180 185 190 Giu Val Thr Cys Vai Val Val Asp Val Gly Gin Giu Asp Pro Giu Val 195 200 205 Ser Phe Asn Gly Thr Leu Met Ala Lys Pro Asn .210 215 <210> 13 <211> 216 <212> PRT 8<213> Llama llama 6 0. <400> 13 Ile Arg Leu Leu Val Giu Ser Gly Gly Gly Leu Val Gin Ala Gly Gly 1 5 10 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Val Phe Thr Phe Asp Asp 25 Tyr Ala Ile Ala Trp Phe Arg Gin Ala Pro Gly Lys Glu Arg Glu Gly 40 Val Ser Cys Ile Ser Thr Ser Asp Gly Ser Thr Tyr Tyr Gly Gly Ser 55 Val Lys Gly Arg Phe Thr Ile Ser Val Asp Val Ala Lys Asn Thr Val 70 75 Tyr Leu Gin Met Asn Ser Leu Lys Pro Asp Asp Thr Ala Val Tyr Tyr 90 Cys Ala Ala Asp Pro Arg Ile Trp Leu His Ser Val Val Gin Gly Thr 100 105 110 Giu Arg Cys Leu Thr Asn Asp Tyr Asp Tyr Trp Gly Gin Gly Thr Gin 115 120 125 Val Thr Val Ser Ser Giu Leu Lys Thr Pro Lys Pro Gin Pro Gin Pro 73 Gin 145 Cys Pro Cys Gly 130 Pro Pro Lys Val Thr 210 Gin Al a Pro Val 195 Leu Pro Gin Leu 150 Pro Glu Leu 165 Lys Asp Val 180 Val Asp Val Met Ala Lys 135 140 Asn Pro Thr Thr Giu Ser Lys Cys Pro Lys 155 160 Leu Gly Gly Pro Ser Val Phe le Phe Pro 170 175 Leu Ser Ile Ser Gly Arg Pro Giu Val Thr 185 190 Gly Gin Glu Asp Pro Giu Val Ser Phe Asn 200 205 Pro Asn 215 Ile Ser Tyr Val Val Tyr Cys Lys Val Gin 145 Ala Pro Val Leu <210> <211> <212> <213 <400> Arg Leu Leu Thr Tyr Ile 35 Ser Cys s0 Lys Gly Len Gin Thr Ala Cys Pro 115 Ser Ser 130 Pro Gin Pro Glu 14 Leu Val Glu Ser Gi) 5 Leu Ser Cys Glu Th-i 20 Gly Trp Ile Arg Gin 40 Ile Ser Gly Arg Asp 55 Arg Phe Thr Ile Ser 70 Met Asn Asn Leu Lys 85 Asn Leu Gly Leu Arg 100 Tyr Giu Tyr Asp Tyr 120 Glu Pro Lys Thr Pro 135 Pro Asn Pro Thr Thr 150 Leu Leu Gly Gly Pro 165 Val Leu Ser Ile Ser 180 Val Gly Gin Gin Asp 200 Ser Arg Ile 14 214

PRT

Llama llama Gly Gly Leu Vai Gln Pro Gly Gly 10 Phe 25 Al a Gly Arg Pro Pro 105 Trp Lys Gin Ser Gly 185 Gly Pro Thr Asp Glu 90 Ser Gly Pro Ser Val 170 Arg Val Gly Ala Asn 75 Asp Asp Gin Gin Lys 155 Phe Pro Sei Ar5 Ala Al a Thr Phe Gly Pro 140 Cys Ile Glu 7Thr Gin Tyr *Lys *Ala Asn Thr 125 Gin Pro Phe Val Phe 205 Ser Axg Al a Asn Asp Arg 110 Gin Pro Lys Pro Thr Asp Glu Asp Thr Tyr Giy Val Gin cys Pro 1.75 -ys Tyr Arg Ser Vai Tyr Tyr Thr Pro Pro 160 Lys Val Lys Va Met 210 Asp Asp 195 Al a Pro Gin Val Ser A~sn Gly Thr <210> <211> <212> <213> 204

PRT

Llama llama <400> Ile Arg Leu 1 Ser Len Arg Len Val Glu 5 Leu Ser Cys Ser Gly Gly Gly Leu Val Gin Ala Gly Gly 10 Ala Ala Ser Gly Val Len Thr Phe Asp Asp 74 Tyr Asp Ile Trp Phe Arg Gin 40 Pro Giu Lys Asp Arg Giu Gly 4*

C

a.

a Val Val Tyr Cys Cys Val Gin 145 Ala Pro Vai Giu

I

Pro Leu Gly Giu 65 Thr Thr Pro Gin Val 145 Val Asn Arg Ser Cys Ile Lys Giy Arg Leu Gin Ile Ala Ala Vai 1.00 Thr Asp Leu 115 Ser Ser Glu 130 Pro Leu Pro Pro Glu Leu Lys-Asp Val 180 Val Asp Val 195 <210> 16 <211> 231 <212> PRT <213> Liai <400> 16 Pro His Gly Gly Gly Pro 20 Ser Ile Ser Lys Giu Asp 50 Val Arg Thr.

Tyr Arg Val Gly Lys Giu 100 Ile Glu Arg 115 Val Tyr Thr 130 Ser Vai Thr Giu Trp Gin Thr Pro Pro 180 Leu Ser Val 195 Ser Phe Asn Arg Tyr Pro Asri Leu 165 Leu Al a Thr 70 Ser Ser Leu Lys Pro 150 Gly Ser Thr 5 Ile Leu Trp Giu Thr 135 Thr Gly Ile Asp Ser Gin Val1 Val 120 Pro Thr Pro Ser Asp 200 Asn Ser Pro Lys 105 Tip Lys Giu Ser Giy 185 Thr Asn Glu 90 Ser Gly Pro Ser Val 170 Arg Thr Asn 75 Asp Ile Gin Gin Lys 155 Phe Pro Tyr Ala Thr Tyr Gly Pro 140 Cys Ile Giu Tyr Glu Al a Ser Thr 125 Gin Pro Phe Val1 Ser Asn Val1 Arg 110 Leu Pro Lys Pro Thr 190 Asp Thr Tyr Thr Val Gin Cys Pro 175 Cys Ser Val His Tip Thr Pro Pro 160 Lys Val Gly Gin Giu Pro Ser Arg Ile .a llama Gly Ser Gly Pro Ala Val Phe rhr Leu Cys Arg 165 Gln Giy Cys Thr Cys Pro Gin Cys Pro Ala Pro Glu Leu Val Arg Glu Asn 70 Ser Lys Ile Ala Leu 150 Asn Leu Lys Phe Pro Val 55 Thr Val Cys Ser Pro 135 Vai Gly Asp Asn Val Giu 40 Asn Lys Leu Lys Lys 120 His Lys Gin Asn Thr 200 Phe 25 Vai Phe Pro Pro Val 105 Al a Arg Gly Pro Asp 185 Trp Pro Thr Asri Lys Ile 90 Asri Lys Giu Phe Giu 170 Gly GIn Pro Cys Trp Glu 75 Gin Asri Giy Giu Tyr 155 Ser Thr Arg Lys Val Tyr Glu His Lys Gin Leu 140 Pro Giu Tyr Gly Pro Vai Ile Gin Gin Ala Thr 125 Ala Ala Gly Phe Glu 205 Lys Val Asp Phe Asp Leu 110 Arg Lys Asp Thr Leu 190 Thr Asp Asp Gly Asn Trp Pro Giu Asp Ile Tyr 175 Tryr Leu Val Val Val Ser Leu Ala Pro Thr Asn 160 Ala Ser Thr 75 Cys Val Val Met His Glu Ala Leu His Asn His Tyr Thr Gin Lys Ser 210 215 220 Ile Thr Gin Ser Ser Gay Lys 225 230 <210> 17 <211> 231 <212> PRT <213> Llama llama Glu Pro Leu Gly Glu Thr Thr Pro Gin Val 145 Val Asn Lys Cys Ile 225 <400> 17 Pro His Gly Gly Gly Gly Pro Ser Ser Ile Ser Gly Lys Giu Asp Pro Val Arg Thr Ala Tyr Arg Vai Val Gay Lys Giu Phe 100 Ile Glu Arg Thr 115 Val Tyr Thr Leu 130 Ser Val Thr Cys Glu Trp Gin Arg 165 Thr Pro Pro Gin 180 Leu Ser Val Gly 195 Val Val Met His 210 Thr Gin Ser Ser 10 is Val Arg Glu Asn 70 Ser Lys Ile Ala Leu 150 pAsn Leu Lys Phe Val Phe 25 Pro Giu Vai 40 Val Asn Phe 55 Thr Lys Pro Val Leu Pro Cys Lys Vai 105 Ser Lys Ala 120 Pro His Arg 135 Val Lys Gly Gly Gin Pro Asp Asn Asp 185 Asn Thr Trp Pro Thr Asn Lys Ile 90 Asn Lys Giu Phe Glu 170 Gly Gln Prc Cys Trp Glu 75 Gin Asn Gly Glu Tyr 155 Ser Thr Arg Lys Val1 Tyr Giu His Lys Gin Leu 140 Pro Giu Tyr Giy Tyr 220 Pro Val Ile Gin Gin Al a Thr 125 Ala Ala Gly.

Phe Glu Lys 30 Val Asp Phe Asp Leu 110 Arg Lys Asp rhr 1.eu 190 ['hr As5 Asp Gly Asn Trp Pro Glu Asp Ile Tyr 175 Tyr Leu Val Val Val Ser Leu Val Pro Thr Asn 160 Al a Ser r'hr Cys Thr Cys Pro Gin Cys Pro Ala Pro Giu Leu Glu Ala 215 31y Lys Leu His Asn His Thr Gin Lys Ser <210> <211> <212> <213> 18 246

PRT

Llama llama <400> 18 Giu Pro Lys 1 Pro Thr Thr Gly Gly Ser Ile Thr Pro Lys Pro Gin Pro Gin Pro Gin Pro Gin Pro Asn 5 10 Giu Ser Lys Cys Pro Lys Cys Pro Ala Pro Glu Leu Leu 25 Ser Val Phe Ile Phe Pro Pro Lys Pro Lys Asp Val Leu 40 Gly Arg Pro Glu Val Thr Cys Val Val Val Asp Vai Gly 55 Pro Ser 76 Gin Glu Asp Pro Giu Val Ser Phe Asn Trp Tyr Ile Asp Gay Ala GJlu 7f '7 CZ Val Axg Thr Ala Asn Thr Arg Pro Lys Giu Glu Gin Phe Asn 0 u Tyr Giy Ile Val 14S Ser Giu Thr Leu Val 225 Thr *Arg *Lys Giu 130 Tyr Val Trp Pro Ser 210 Val Gin Vai Giu 115 Lys Thr Thr Gin Pro 195 Val Val.

100 Phe Thr Leu Cys Arg 180 Gin Giy Ser Lys Ile Al a Leu 165 Asn Leu Lys Val Cys Ser Pro 150 Val1 Gly Asp Leu Lys Lys 135 His Lys Gin Asn Pro Val 120 Ala Arg Gly Pro Asp Ile 105 Asn Lys Giu Phe Giu 185 Gly 90 Gin Asn Gly Giu Tyr 170 Ser Thr His Lys Gin Leu 155 Pro Giu Tyr Gin Al a Thr 140 Ala Pro Gly Phe Asp Leu 125 Arg Lys Asp Thr Leu Trp 110 Pro Giu Asp Ile Tyr 190 Tyr Ser Leu Al a Pro Thr Asn 175 Aila Ser Thr Thr Pro Gin Val 160 Val1 Thr Lys Asn Thr Trp Gin Gin Gly Giu Thr Phe Thr Cvs 215 Met His Glu Ala Leu 230 Ser Ser Giy Lys 245 220 His Asn His Tyr 235 Thr Gin Lys Ser Ile 240 <210> 19 <211> 248 <212> PRT <213> Llama llama

S.

S

*5

S.

Glu Pro Leu Val Val Al a Ser Leu Ala Pro 145 Thr Asn Ala <400> 19 Pro Lys Thr Pro 5 A-sn Pro Thr Thr 20 Leu Gly Gly Pro Leu Ser Ile Ser 5o Gly Gin Giu Asp Giu Val Arg Thr Thr Tyr Arg Val 100 Thr Gly Lys Glu 115 Pro Ile Glu Lys 130 Gin Val Tyr Thr Val Ser Val. Thr 165 Val Giu Trp Gin 180 Thr Thr Pro Pro Lys Pro Gin Pro Gin Pro Gin Pro Gin Pro Gln 10 Giu Ser Lys cys Ser Gly Pro 70 Al a Val Phe Thr Leu 150 Cys Arg Val Arg 55 Giu Asn Ser Lys le 135 Al a Leu Asn Phe 40 Pro Val Thr Val Cys 120 Ser Pro Val Gly 25 le Glu Ser Arg Leu 105 Lys Lys His Lys Gin Pro Phe Val Phe Pro Pro Val.

Al a Arg Gly 170 Pro Lys Pro Thr Asn 75 Lys Ile Asn Lys Giu 155 Phe Glu Cys Pro Cys Trp Glu Gin Asn Gly 140 Giu Tyr Ser Pro Lys Val Tyr Giu His Lys 125 Gin Leu Pro Glu Ala Pro Val1 Ile Gin Gin 110 Ala Thr Ala Pro Gly Pro Lys Val Asp Phe Asp Leu Arg Lys Asp 175 Thr Glu Asp Asp Gly Asn Trp Pro Giu Asp 160 Ile Tyr Gin Leu Asp Asn Asp Gly Thr Tyr Phe Leu Tyr 77 Ser Thr 225 Ser 1.95 Lys Leu 210 Cys Val Ile Thr 200 205 Ser Val Gly Lys Asn Thr Trp Gin Gin Gly Giu Thr Phe 215 220 Val Met His Giu Ala Leu His Asn His Tyr Thr Gin Lys 230 235 240 Gin Ser Ser Gly Lys 245 <210> <211> 250 <212 PRT a a Giu Pro Pro Lys Val 65 Asp Phe Asp Leu Arg 145 Lys Asp Thr Leu Thr 225 Gin Al a 1 Pro <213> <400> Pro Lys Gin Pro Giu Leu Asp Val Asp Val Giy Ala Asn Ser Trp Leu 115 Pro Ala 130 Glu Pro Asp Thr Ile Asn Tyr Ala 195 Tyr Ser 210 Phe Thr Lys Ser <210> <211> <212> <213> <400> His His Giu Leu Thr Asn 20 Leu Leu Gly Giu Thr 100 Thr Pro Gin Vai Val1 180 Thr Lys Cys Ile Llama llama *Pro Pro Gly Ser Gin Val Tyr Gly Ile Val Ser 165 Giu Thr Leu Val Thr 245 Lys Thr Gly Ile Glu 70 Arg Arg Lys Glu Tyr 150 Val Trp Pro Ser Val 230 Gin Pro Thr Pro Ser Asp Thr Val Glu Lys 135 Thr Thr Gin Pro Val 215 Met Ser Gin *Giu Ser 40 Gly Pro Ala Val Phe 120 Thr Leu Cys Arg Gin 200 Gly His Ser Prc Sex 25 Vali Arg Glu Asn Ser 105 Lys Ile Ala Leu Asn 185 Leu Lys Giu Gly Gin *Lys Phe Pro Val1 Thr 90 Val Cys Ser Pro Val1 170 Giy Asp Asn Ala Lys 250 Pro Cys Ile Giu Ser 75 Arg Leu Lys Lys His 155 Lys Gin Asn Thr Leu 235 Gin Pro Phe Val Phe Pro Pro Vai Ala 140 Arg Giy Pro Asp Trp 220 His Pro Lys Pro Thr Asn Lys Ile Asn 125 Lys Giu Phe Glu Gly Gin Asn Gin Cys Pro Cys Trp Giu Gin Asn Gly.

Glu Tyr Ser 190 Thr Gin His Pro Pro Lys Val Tyr Glu His Lys Gin Leu Pro 175 G1u ryr 3iY Pyr Gin Ala Pro Val Ile Gin Gin Al a Thr Ala 160 Pro Giy Phe Giu Thr 240 21 234

PRT

Llama llama 21 Ser Giu Asp Pro Thr Ser Lys Cys Pro Lys Cys Pro Gly 5 10 Leu Gly Gly Pro Thr Val Phe Ile Phe Pro Pro Lys Ala 78 Lys Asp Val Val Asp Leu Asp Leu Arg Lys 145 Asp Thr Leu Val Gin 225 Asp Gly Asn Trp, Pro Giu, 130 Asp Ile Tyr Tyr Phe 210 Lys Val1 Thr Ser Leu.

Ala 115 Pro Thr Asn Al a Ser 195 Thr Ser Leu Gly Glu Thr Thr 100 Pro Gin Val1 Vai Asn 180 Lys Cys Ile Ser Ile Thr Arg 40 Lys Val1 Tyr 8S Giy Ile Vali Ser Glu 165 Thr Leu Val1 Thr Giu His 70 Arg Lys Giu Tyr Val1 i5o Trp Pro Ser Val Gin 230 Asp 55 Thr Val Giu Arg Thr 135 Thr Gin Pro Vai Met 215 Ser Pro Al a Val1 Phe Thr 120 Leu Cys Arg Gin Giy 200 His Ser 25 Lys Glu Giu Ser Lys 105 Ile Al a Leu Asn Leu 185 Lys Glu Gly Cys Val Val Pro Giu Val Thr Ile Thr Val 90 Cys Ser Pro Val Gly 170 Asp Asn Ala Lys Aesn Phe Lys Pro 75 Leu Pro Lys Val Lys Ala His Arg 140 Lys Gly 155 Gin Pro Asn Asp Thr Trp Leu His 220 Ser Lys Ilie Asn Lys 125 Giu Phe Glu Gly Gin 205 Asn Trp Glu Gln Asn 110 Gly Glu Phe Ser Thr 190 Gin His Ser Giu His Lys Gin Leu Pro G-lu 1.75 Tyr Gly Ser Val Gin Gin Ala Thr Ala Ala 160 Gly Phe Giu Thr 'S

S.

S

*5 4*

S.

a

S.

<210> 22 <211> 81 <212> DNA <213> Artificial Sequence <220> <223> Primer <400> 22 tgtaagcttg ccaccatgga ttgggtgtgg accttgctat tcctgttgtc agtaactgca ggtgtccact cccaggtgca g <210> 23 <211> 38 <212> DNA <213> Artificial Sequence <400> 23 gcaggtgtcc actcccaggt gcagctgaag gagtcagg <210> 24 <211> 48 <212> DNA <213> Artificial. Sequence <400> 24 tcttctaagc ttagttgtct tgagctccag ctgaaggagt caggacct 79 <210> <211> <212 DNA <213> Artificial Sequence <400> ctgaaggagt caggacctgg cctggtgacg ccct cacaga gcctg <210> 26 <211> <212> DNA <213> Artificial Sequence <400> 26 acgccctcac agagcctgtc catcacttgt actgtctctg ggttt <210> 27 <211> <212> DNA :<213> Artificial Sequence <400> 27 tgtactgtct ctgggttttc attaagcgac tatggtgttc attgg <210> 28 <211> 51 <212> DNA <213> Artificial Sequence <400> 28 gactatggtg. ttcattgggt tcgccagtct ccaggacagg gactggagtg c 51 <210> 29 <211> 51 <212> DNA <213> Artificial Sequence 29 gactatggtg ttcattggtt ccgccagtct ccaggacagg agcgcgaggg t, 51 <210> <211> 51 <212> DNA <213> Artificial Sequence <400> gactatggtg ttcattggta ccgccagtct. ccaggacagg agcgcgagtt c 51 <210> 31 <211> 51 <212> DNA <213> Artificial Sequence <400> 31 gcactccagt ccctgtcctg gagactggcg aacccaatga acaccatagt c 51 80 <210> 32 <211> 51 <212> DNA <223> Artificial Sequence <400> 32 accctcgcgc tcctgtcctg gagactggcg gaaccaatga acaccatagt c 51 <210> 33 <211> 51 <212> DNA <213> Artificial Sequence <400> 33 gaactcgcgc tcctgtcctg gagactggcg gtaccaatga acaccatagt c 51 <210> 34 <211> 44 <212> DMA <213> Artificial Sequence <400> 34 ccagcccata ttactcccag gcactzccagt ccctgtcctg gaga 44 <210> <211> 44 <212> DNA <213> Artificial Sequence <400> ccagcccata ttactcccag accctcgcgc tcctgtcctg gaga 4 <210> 36 <211> 44 <212> DNA <213> Artificial Sequence <400> 36 ccagcccata ttactcccag gaactcgcgc tcctgtcctg gaga 44 <210> 37 <211> 42 <212> DNA <213> Artificial Sequence <400> 37 gagagccgaa ttataattcg tgcctccacc agcccatatt ac 42 <210> 38 <211> 42 <212> DNA <213> Artificial Sequence <400> 38 tttgctgatg ctctttctgg acatgagagc cgaattataa tt 42 -81 <210> 39 <211> 42 <212> DNA <213> Artificial Sequence <400> 39 gaaaacttgg cccttggagt tgtctttgct gatgctcttt ct 42 <210> <211> 42 <212> DNA <213> Artificial Sequence <400> agcttgcaga ctcttcattt ttaagaaaac ttggcccttg ga 42 <210> 41 <211> 42 <212> DNA <213> Artificial Sequence <400> 41 acagtaatac acggctgtgt catcagcttg cagactcttc at 42 <210> 42 <211> 42 <212> DNA <213> Artificial Sequence <400> 42 ataggagtat cccttatctc tggcacagta atacacggct gt 42 <210> 43 <211> 42 <212> DNA <213> Artificial Sequence <400> 43 accccagtag tccatagaat agtaatagga gtatccctta tc 42 <210> 44 <211> 42 <212> DNA <213> Artificial Sequence <400> 44 gacggtgact gaggttcctt gaccccagta gtccatagaa. ta 42 <210> <211> 36 <212> DNA <213> Artificial Sequence <400> tcttctggat. ccagaggaga cggtgactga ggttcc 36 82 <210> 46 <211> 57 <212> DNA <213> Artificial Sequence <400> 46 ctgtctagac ctgctagcag aggagacggt gactgaggtt ccttgacccg agtagtc 57 <210> 47 <212> <212> DNA <213> Artificial Sequence <220> <223> Primer <400> 47 ctcgtggart ctggaggagg *<210> 48 :<211> 44 <212> DNA <213> Artificial Sequence <220> <223> Primer <400> 48 cgtcatgtcg acggatccaa gctttgagga gacggtgacy tggg 44 <210> 49 <211> 23 <212> DNA :<213> Artificial Sequence S<400> 49 caggtgcagc tggtgcagtc tgg 23 :<211> 21 <212> DNA <213> Artificial Sequence <220> <223> Primer <400> ggttgtggtt ttggtgtctt g 21 <210> 51 <211> 24 <212> DNA <213> Artificial Sequence <220> <223> Primer 83 <400> 51 caggtcaact. taaagggagt ctgg 24 <210> 52 <211> 22 <212> DNA <213> Artificial Sequence <400> 52 aggtgcagc tgcaggagtc gg 22 <210> 53 <211> 23 <212> DNA <213> Artificial Sequence <400> 53 taatacgact cactataggg aga 23 .<210> 54 :<211> DNA <213> Artificial Sequence <400> 54 aacagctatg accatg 16 <210> <211> 36 <212> DNA <213> Artificial Sequence <400> Sg'cgctcgagc ccaccatgca gtcgggcact cactgg 36 <210> 56 <211> 36 <212> DNA <213> Artificial Sequence 56 ggccggatcc ggatccatct ccatgcagtt ctcaca 36 <210> 57 <211> 38 <212> DNA <213> Artificial Sequence <400> 57 gcgataaagc tgccaccatg gaacatagca cgtttct c 38 <210> 58 <211> <212> DNA <213> Artificial Sequence 84 <400> 58 gcgggatcca tccagctcca cacagctctg <210> 59 <211> 39 <212> DNA <213> Artificial Sequence <400> 59 gcgataaagc ttgccaccat ggaacagggg aagggcctg <210> <211> 34 <212> DNA <213> Artificial Sequence <400> gcgggatcca tttagttcaa tgcagttctg agac <210> 61 <211> 16 <212> PRT <213> Mus rnusculus

S.

S

S S *5

S.

S

S.

S

S

S

S.

<400> 61 Cys Arg Ser Tyr 1 Ala Tyr Tyr Asp Tyr Asp Gly Ile Ala Tyr Cys Trp 5 10 <210> <211> <212> <213> 62 1s

PRT

Mus rusculus Tyr 1 <400> 62 Cys Ser Ala Tyr Tyr Asp Tyr Asp Gly Ile Ala Tyr Cys Trp 5 10 <210> 63 <211> 14 <212> PRT <213> Mus musculus <400> 63 Cys Ala Tyr Tyr 1 Tyr Asp Tyr Asp Gly Ile Ala Tyr Cys Ti-p 5 <210> <211> <212> <213> 64

PRT

Mus musculus <400> 64 Cys Arg Tyr Tyr

I

Tyr Asp Asp His Tyr Ser Leu Asp Tyr Cys Ti-p 5 10 <210> 85 <211> <212> <213> :14

PRT

Mus trusculus <400> Tyr Cys Tyr Tyr 1 Asp Asp His Tyr Ser Leu Asp Tyr Cys Trp 5 <210> <211> <212> <213> 66 13

PRT

Mus musculus <400> 66 Cys Tyr Asp Asp His Tyr Ser Leu Asp Tyr Cys Trp a a a C a a

S.

a a.

a a.

<210> <211> <212> <213> <400> Cys Asp Tyr

I

67 12

PRT

mus musculus 67 Asp His Tyr Ser Leu Asp Tyr Cys Trp 5 68 11

PRT

Mus rnusculus <210> <211> <212> <213> Tyr 1 <400> 68 Cys Asp His <210> 69 <211> 14 <212> PRT <213> Mus <400> 69 Cys Ala Arg Tyr Ser Leu Asp Tyr Cys Trp 5 musculus Asp Ser Asp Trp, Tyr Phe Asp Val Cys Trp, 5 Tyr 1 <210> <211> <212> <213> 13

PRT

Mus musculus <400> Tyr Cys Ala Arg

I

Ser Asp Trp Tyr Phe Asp Val Cys Trp 5 <210> 71 <211> 12 <212> PRT 86 <213> Ntis rnusculus <400> 71 Cys Ala Arg Tyr 1 Asp Trp Tyr Phe Asp Val Cys Trp 5 <210> <211> <212> <213> 72 14

PRT

Mus musculus <400> 72 Cys Gly Tyr Tyr

I

Ser Tyr Tyr Tyr Ser Met Asp Tyr Cys Trp 5 <210> <211> <212> <213> 73 13

PRT

Mus musculus

C

C C

C

<400> 73 Cys Tyr Ser Tyr Tyr Tyr Ser Met Asp Tyr Cys Trp 5 <210> <211> <212> <213> 74 12

PRT

Mus musculus C. C

C.

C. 'C C

C.

CC C C Tyr 1 <400> 74 Cys Ser Tyr Tyr Tyr Ser Met Asp Tyr Cys Trp, 5 <210> <211> <212> <213> 9

PRT

mus musculus <400> Tyr Cys Tyr Asp 1 Tyr Asp Gly Cys Tyr <210> c211> <212> <213>; 76 9

PRT

Mus musculus <400> 76 Tyr Cys Tyr Asp 1 Tyr Asp Tyr Cys Tyr <210> 77 <211> 9 <212> PRT <213> Mus musculus -87- <400> 77 Tyr Cys Tyr Asp

I

Tyr Asp Phe Cys Tyr <210> 78 <211> 9 <212> PRT <213> Mus musculus <400> 78 Cys Tyr Asp Asp His Thr Cys Tyr <210> <211> <212> <213> 79 9

PRT

Mus musculus

S

*5

S.

<400> 79 Cys Tyr Asp Tyr 1 Asp His Gin Cys Tyr <210> <211> 9 <212> PRT <213> Mus musculus <400> S0 Cys Phe Asp S.

S

S

S..

S

S.

S. S S Tyr 1 Trp Asn Cys Tyr 88

Claims (3)

1. A recombinant soluble human CD3 heterodimeric polypeptide, wherein said polypeptide comprises a CD3-epsilon chain, and wherein said polypeptide can be bound by an anti-CD3 monoclonal antibody that binds only to native conformational epitopes.

2. The recombinant soluble human CD3 heterodimeric polypeptide of claim 1, comprising a CD3 delta chain.

3. The recombinant soluble human CD3 heterodimeric polypeptide of claim 1, further comprising a CD3 gamma chain. DATED this 1 8 t h day of March, 2004 XCYTE THERAPIES, INC. by its Patent Attorneys DAVIES COLLISON CAVE *o oo*